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Abstract
Background
Febrile seizures occurring in a child older than one month during an episode of fever affect 2% to 4% of children in Great
Britain and the United States and recur in 30%. Rapid-acting antiepileptics and antipyretics given during subsequent fever
episodes have been used to avoid the adverse effects of continuous antiepileptic drugs.
Objectives
To evaluate primarily the effectiveness and safety of antiepileptic and antipyretic drugs used prophylactically to treat children
with febrile seizures; but also to evaluate any other drug intervention where there was a sound biological rationale for its use.
Search methods
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We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2016, Issue 7);
MEDLINE (1966 to July 2016); Embase (1966 to July 2016); Database of Abstracts of Reviews of Effectiveness (DARE)
(July 2016). We imposed no language restrictions. We also contacted researchers in the field to identify continuing or
unpublished studies.
Selection criteria
Trials using randomised or quasi-randomised participant allocation that compared the use of antiepileptic, antipyretic or other
plausible agents with each other, placebo or no treatment.
Data collection and analysis
Two review authors (RN and MO) independently applied predefined criteria to select trials for inclusion and extracted the
predefined relevant data, recording methods for randomisation, blinding and exclusions. For the 2016 update a third author
(MC) checked all original inclusions, data analyses, and updated the search. Outcomes assessed were seizure recurrence at
6, 12, 18, 24, 36, and 48 months and at age 5 to 6 years in the intervention and non-intervention groups, and adverse
medication effects. We assessed the presence of publication bias using funnel plots.
Main results
We included 40 articles describing 30 randomised trials with 4256 randomised participants. We analysed 13 interventions of
continuous or intermittent prophylaxis and their control treatments. Methodological quality was moderate to poor in most
studies. We found no significant benefit for intermittent phenobarbitone, phenytoin, valproate, pyridoxine, ibuprofen or zinc
sulfate versus placebo or no treatment; nor for diclofenac versus placebo followed by ibuprofen, acetaminophen or placebo;
nor for continuous phenobarbitone versus diazepam, intermittent rectal diazepam versus intermittent valproate, or oral
diazepam versus clobazam.
There was a significant reduction of recurrent febrile seizures with intermittent diazepam versus placebo or no treatment, with
a risk ratio (RR) of ¬0.64 (95% confidence interval (CI) 0.48 to 0.85 at six months), RR of 0.69 (95% CI 0.56 to 0.84) at 12
months, RR 0.37 (95% CI 0.23 to 0.60) at 18 months, RR 0.73 (95% CI 0.56 to 0.95) at 24 months, RR 0.58 (95% CI 0.40 to
0.85) at 36 months, RR 0.36 (95% CI 0.15 to 0.89) at 48 months, with no benefit at 60 to 72 months. Phenobarbitone versus
placebo or no treatment reduced seizures at 6, 12 and 24 months but not at 18 or 72 month follow-up (RR 0.59 (95% CI 0.42
to 0.83) at 6 months; RR 0.54 (95% CI 0.42 to 0.70) at 12 months; and RR 0.69 (95% CI 0.53 to 0.89) at 24 months).
Intermittent clobazam compared to placebo at six months resulted in a RR of 0.36 (95% CI 0.20 to 0.64), an effect found
against an extremely high (83.3%) recurrence rate in the controls, which is a result that needs replication.
The recording of adverse effects was variable. Lower comprehension scores in phenobarbitone-treated children were found
in two studies. In general, adverse effects were recorded in up to 30% of children in the phenobarbitone-treated group and in
up to 36% in benzodiazepine-treated groups. We found evidence of publication bias in the meta-analyses of comparisons for
phenobarbitone versus placebo (eight studies) at 12 months but not at six months (six studies); and valproate versus placebo
(four studies) at 12 months, with too few studies to identify publication bias for the other comparisons.
Most of the reviewed antiepileptic drug trials are of a methodological quality graded as low or very low. Methods of
randomisation and allocation concealment often do not meet current standards; and treatment versus no treatment is more
commonly seen than treatment versus placebo, leading to obvious risks of bias. Trials of antipyretics and zinc were of higher
quality.
Authors' conclusions
We found reduced recurrence rates for children with febrile seizures for intermittent diazepam and continuous
phenobarbitone, with adverse effects in up to 30%. Apparent benefit for clobazam treatment in one trial needs to be
replicated to be judged reliable. Given the benign nature of recurrent febrile seizures, and the high prevalence of adverse
effects of these drugs, parents and families should be supported with adequate contact details of medical services and
information on recurrence, first aid management and, most importantly, the benign nature of the phenomenon.
Plain language summary
Prophylactic drug management for febrile seizures in children
Background
Seizures occurring with a fever in children are common and affect about one in thirty under the age of six years. On average,
one out of three children who have had a febrile seizure will have at least one more. We reviewed the evidence about the
effect of drugs to prevent seizures (antiepileptics), drugs to lower temperature (antipyretics) and zinc on children with febrile
seizures.
Objective
We wanted to know in how many children these drugs would prevent a recurrence or bring unwanted effects.
Methods
We included 30 studies with a total of 4256 children in the review. Children who had had at least one febrile seizure were put
into groups who either had the study treatment or not. The studies recorded any further seizures at various time intervals
between 6 months and up to 6 years of age in each group. Unwanted medication effects were also noted.
Results
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The quality of study design and evidence provided by these studies was often low or very low for the antiepileptic drugs. Poor
methods known to lead to obvious risks of bias were used. This was to do with the way children were put in each group and
how random this allocation was. Other issues included whether the parents and/or doctors knew which group each child was
in or perhaps if the study was of treatment compared to no treatment. The quality of trials of antipyretics or zinc was better,
with the evidence graded moderate to high.
Zinc therapy gave no benefit. Nor was there benefit in treating children just at the time of the fever with either antipyretic
drugs or most antiepileptic drugs.
At times a significant result was noted. In statistics this means there was a less than 1 in 20 chance of this happening by
chance. For example, at times between 6 and 48 months follow-up, intermittent diazepam (an antiepileptic drug) led to a
reduction in the number of recurrent seizures by about a third. Continuous phenobarbitone resulted in significantly fewer
recurrences at 6, 12 and 24 months, but not at 18 and 60 to 72 months
However, as recurrent seizures are only seen in about a third of children anyway this means that up to 16 children would
have to be treated over a year or two to save just one child a further seizure. As febrile seizures are not harmful we viewed
these significant findings (in the statistical sense) to be unimportant. This is particularly so as adverse effects of the
medications were common. Lower comprehension scores in phenobarbitone-treated children were found in two studies. In
general, adverse effects were recorded in up to about a third of children in both the phenobarbitone and benzodiazepine-
treated groups. The benefit found for treatment with clobazam in one study published in 2011 needs to be repeated to show
that this finding is reliable.
Author’s conclusions
Neither continuous nor intermittent treatment with zinc, antiepileptic or antipyretic drugs can be recommended for children
with febrile seizures. Febrile seizures can be frightening to witness. Parents and families should be supported with adequate
contact details of medical services and information on recurrence, first aid management and, most importantly, the benign
nature of the phenomenon.
The evidence is current to 21 July 2016.
Background 
Description of the condition
The International League Against Epilepsy (ILAE) defines a febrile seizure as “a seizure occurring in childhood after one
month of age associated with a febrile illness not caused by an infection of the central nervous system, without previous
neonatal seizures or a previous unprovoked seizure, and not meeting the criteria for other acute symptomatic seizures”
(ILEA 1993). The cumulative incidence of febrile seizures is estimated between 2% and 5% in the US and Western
Europe, (Shinnar 2003; Verity 1991) between 6% to 9% in Japan, and 14% in India and Guam (ILEA 1993). Febrile
seizures have a peak incidence at 18 months and are most common between the ages of six months and six years. (Berg
1996; Hauser 1994; Offringa 1991)
In 2010 the ILAE proposed that febrile seizures could be organised by typical age at onset (that is, infancy and
childhood). Conventionally, febrile seizures have been classified as simple or complex based on duration, recurrence
during the same illness episode, and the presence of focal features. Most febrile seizures are generalised tonic-clonic
seizures, and about 30% - 35% of febrile seizures have one or more complex features (focal onset, duration > 10
minutes, or multiple seizures during the illness episode) (Berg 1996). Febrile status epilepticus, a subgroup of complex
febrile seizures with seizures lasting more than 30 minutes, occur in about 5% of cases (Berg 1996).
Causation is thought to be multifactorial with environmental factors and increasing evidence for genetic factors
contributing to pathogenesis (Audenaert 2006; Offringa 1994). No single susceptibility gene for febrile seizures is
known. In contrast, gene identification has been successful in families with genetic epilepsies with febrile seizures plus
(GEFS+) where kindreds may well include children with Dravet syndrome (Berg 2010; Kasperaviciute 2013; Tang 2013). In
these conditions febrile seizures persist beyond the age of six years; mutations have been found in SCN1A and SCN1B
(both sodium channel genes important for neurotransmission) and GABRG2 (related to γ-aminobutyric acid, an
important inhibitory neurotransmitter) (Audenaert 2006; Baulac 2004; Gérard 2002; Hirose 2003; Johnson 1998, Kananura
2002, Nabbout 2002; Nakayama 2006).
Description of the intervention
Despite the frequent nature of these seizures, debate regarding the optimal management arose at an early stage (Baumann
1999) and continues. After resolution of the acute episode, the possibility of recurrent seizures during subsequent
febrile illnesses must be addressed. This risk of recurrent seizures in previously healthy, untreated children was
estimated in a collaborative study that used the individual data from five follow-up studies with similar definitions of
febrile seizures and risk factors (Offringa 1994). Of 2496 children with 1410 episodes of recurrent seizures in this study, 32%
had at least one, 15% had at least two and 7% had three or more recurrent seizures after a first febrile seizure. The hazard
of recurrent seizures was highest between the ages of 12 and 24 months. A history of febrile or unprovoked seizures in a
first-degree family member, a relatively low temperature at the first seizure, young age at onset (< 12 months), a family
history of unprovoked seizures, and a partial initial febrile seizure were all associated with an increased risk of subsequent
seizures.
If a child is considered at increased risk of frequent or complicated seizures (Berg 1990), prophylactic medication might
be considered. However, such treatment may have adverse effects on the child's behaviour and cognitive
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development. Thus, the decision to treat requires assessment of the potential risks and benefits to the child. Since
1990, at least 300 articles have been published on the drug management of seizures associated with fever (Gram 1984
). This has long been a controversial area, with a persistent variety of opinions on management. Part of this
controversy reflects the fact that it is uncertain whether prophylactic medication with antiepileptics and antipyretics is
effective and has no important adverse effects. Yet, phenobarbital has adverse effects such as irritability,
hyperactivity, and somnolence, and may even lower the cognitive development of the toddlers (Farwell 1990; Herranz 1988).
To avoid the side effects of continuous antiepileptic drugs (AEDs), rapid-acting antiepileptics given only during fever periods
have been used in an attempt to reduce the risk of recurrent febrile seizures. Phenobarbital at times of fever has been
proven ineffective, probably because of the delay in achieving appropriate serum and tissue levels. Thus far, only
prophylactic diazepam, given orally or rectally, has been studied in placebo-controlled trials. The efficacy of intermittent
antipyretic treatment during febrile episodes in the prevention of seizure recurrence has recently been studied.
Newton 1988 assessed the efficacy of phenobarbitone and valproate for the prophylactic treatment of febrile seizures
by summarising the results from all eight British placebo-controlled clinical trials that were done before 1988. Data
were pooled and analysed on an intention-to-treat basis. The overall odds ratio of recurrent febrile seizures for
phenobarbitone was 0.8 and for valproate 1.42; neither result was statistically significant. The author therefore
concluded that neither treatment is to be recommended. A second meta-analysis summarised four published non-
British randomised, placebo-controlled trials that had been done up to 1996 using phenobarbital as a preventive
treatment of febrile seizures (Rantala 1997). The risk of recurrences was lower in children receiving continuous
phenobarbital therapy than in the placebo group (odds ratio 0.54, 95% confidence interval (CI) 0.33 to 0.90). On
average, eight children would have to be treated with phenobarbital for two years continuously to prevent one febrile
seizure (number needed to treat (NNT) 8, 95% CI 5 to 27) (Rantala 1997).
How the intervention might work
The rationale for using prophylactic antiepileptic drugs in children with febrile seizures is to raise seizure threshold in the face
of a potentially triggering fever. Antipyretics are used to attenuate the effect of fever as a triggering factor. Previous studies
demonstrated blood and cerebrospinal fluid zinc levels to be significantly lower in children with a febrile seizure tendency
than in children with afebrile seizures. Zinc level is known to stimulate the excitatory neurotransmitter glutamate and to
increase the inhibitory neurotransmitter gamma-amino-butyric acid.
Why it is important to do this review
We undertook this review to answer the question whether prophylactic treatment with an antiepileptic drug or an antipyretic
can, as compared to no therapy, decrease the likelihood of future febrile seizures in children with febrile seizures.
Objectives 
To evaluate primarily the effectiveness and safety of antiepileptic and antipyretic drugs used prophylactically to treat children
with febrile seizures; and also to evaluate any other drug intervention where there was a sound biological rationale for its
use.
Methods 
Criteria for considering studies for this review 
Types of studies 
We included all trials using randomised or quasi-randomised participant allocation that compared the use of antiepileptic or
antipyretic agents with each other or with placebo or with no treatment.
Types of participants 
Children aged between six months and seven years with a history of febrile seizures and who received treatment with an
antiepileptic drug or an antipyretic drug in an attempt to prevent recurrent seizures. We also planned subgroup analyses of
neurologically healthy children, of children with previous recurrent seizures, and of studies limited to children at a perceived
relatively high risk of recurrence.
Types of interventions 
We included trials if they compared one treatment with another or with placebo (or no treatment) in children with febrile
seizures. Specific drugs included the benzodiazepines (diazepam, lorazepam, clobazam and midazolam), phenytoin,
phenobarbitone, valproate, diclofenac, acetaminophen and ibuprofen. We planned a subgroup analysis of intermittent AED
therapies versus continuous AED therapies, and of antipyretics during episodes of fever versus AED therapy during fever. A
six-month course of zinc (shown previously to have been significantly lower in children with febrile seizures) was evaluated in
one study.
Types of outcome measures 
Primary outcomes
Efficacy - proportion of children with recurrence of febrile or non-febrile seizures at certain time points after treatment onset
(6 months, 12 months, 24 months, 36 months, and at age five years).
Secondary outcomes
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1) Treatment adherence (as measured in the studies).
2) Safety: the incidence of specific adverse unwanted effects, including irritability, hyperactivity, somnolence, impaired
cognitive development for phenobarbital and intermittent diazepam, gastro-enterologic unwanted effects for valproate and
antipyretics, of any administered antiepileptic or antipyretic.
3) As it is of clinical interest, we analysed pooled data at the chosen study time points to estimate the recurrent febrile
seizure risk in the placebo and no-treatment groups. This analysis could provide a useful insight into the natural history of the
disorder.
Search methods for identification of studies 
Electronic searches 
We searched the following databases. We imposed no language restrictions.
a) Cochrane Epilepsy Group Specialised Register (21 July 2016).
b) Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library 21 July 2016).
c) MEDLINE (Ovid) (1950 to 21 July 2016).
d) Embase (1966 to 21 July 2016).
Details of the search strategies used are outlined in Appendix 1.
Searching other resources 
We checked the reference lists of articles identified by the above searches for additional studies. We also contacted
researchers in the field to find any ongoing or unpublished studies.
Data collection and analysis 
Selection of studies 
Two review authors (RN and MO) independently assessed trials for inclusion, resolving any disagreements by discussion.
For the 2016 update, a third review author (MC) checked all original inclusions.
Data extraction and management 
Two review authors (RN and MO) extracted the outcome data specified above as well as the following data, resolving any
disagreements by discussion. For the 2016 update a third review author (MC) checked all data extracted.
Methodological and trial design:
a. method of randomisation;
b. method of double blinding;
c. whether any participants had been excluded from the reported analyses.
Where data were missing, we tried to contact original authors for this information.
Participant and demographic information:
a. total number of participants allocated to each treatment group or audited in any protocol;
b. the proportion of participants in each treatment group with a recurrence at certain time points (6 months, 12 months, 24
months, 36 months, 48 months and 72 months, where these data were available);
c. risk factors associated with recurrent seizures, i.e. age at first seizure below 18 months, positive family history of seizures,
temperature at index seizure below 40.0 °C.
Assessment of risk of bias in included studies
Review author MC made an initial assessment of all included studies for risk of bias using the Cochrane 'Risk of bias'
tool for RCTs (Higgins 2011). This was compared to an independent assessment by either review author RN or MO, with a
third party resolving any disagreements by discussion.
Measures of treatment effect
We treated efficacy (recurrence of febrile or non-febrile seizures) as dichotomous outcomes and expressed them as risk
ratios (RR) with 95% confidence intervals (CIs).
We summarised treatment adherence and incidence of adverse effects narratively according to the definitions
reported in the study. We calculated numbers needed to treat (NNTs) as the reciprocal of the absolute risk reduction
(McQuay 1998).
Unit of analysis issues 
We did not have any unit of analysis issues. Medication dosages were standard. Outcome measures were simply seizure
recurrence. No studies were of a repeated measure (longitudinal) nature or of a cross-over design.
Dealing with missing data
At times recurrence data had to be reconstructed from published survival curves. We were careful to cross-check this with
quoted cumulative incidence rates for in-study data. We cross-checked trial details against any additional published report of
the trial and contacted original trial authors if we found missing data, errors or inconsistencies (although the response was
uniformly poor). No author provided individual patient data (IPD) when requested but we are satisfied with the consistency
8 Prophylactic drug management for febrile seizures in children
5 / 65
checks we performed.
Assessment of heterogeneity 
We assessed clinical heterogeneity by reviewing the differences across trials in the characteristics of recruited participants
and treatment protocols. We assessed statistical heterogeneity using a Chi2 test for heterogeneity. We assessed
heterogeneity using the Q test (P < 0.10 for significance) and the I² statistic (greater than 50% indicating considerable
heterogeneity (Higgins 2003)) and visually by inspecting forest plots.
Assessment of reporting biases
We assessed the presence of publication bias using funnel plots for each meta-analysis that included results of five or more
studies.
Data synthesis
We included studies comparing either different drugs or different treatment approaches, for example intermittent AED
therapies versus continuous AED therapies, antipyretics during episodes of fever versus AED therapy during fever, or all
versus placebo. The primary analysis was intention-to-treat and included all randomised participants analysed in the
treatment group to which they were allocated, irrespective of which treatment they actually received.
We conducted meta-analysis if sufficient data were available, that is at least two trials looking at the same two treatments
and the same outcomes. All meta-analyses were conducted using a fixed-effects model, regardless of the presence of
heterogeneity. If we had concerns regarding variability of study design and whether pooling data was appropriate, meta-
analysis would not have been conducted.
We conducted meta-analysis only for the primary outcome of efficacy (recurrence of febrile or non-febrile seizures).
We summarised treatment adherence and incidence of adverse effects narratively according to the definitions reported in the
study; we did not pool numerical data for these outcomes, due to variability in definitions and the level of detail reported in
the studies.
Subgroup analysis and investigation of heterogeneity 
We had no hypotheses needing subgroup analyses.
Sensitivity analysis
We felt no need for any sensitivity analyses as misdiagnosis of febrile seizures or their recurrence is unlikely within the
reported study groups.
Summary of Findings and Quality of the Evidence (GRADE)
In a post hoc change from protocol, we present 13 'Summary of findings' tables (Summary of findings table 1; Summary of
findings table 2; Summary of findings table 3; Summary of findings table 4; Summary of findings table 5; Summary of
findings table 6; Summary of findings table 7; Summary of findings table 8; Summary of findings table 9; Summary of
findings table 10; Summary of findings table 11; Summary of findings table 12; Summary of findings table 13); one for each
comparison of the review.
The primary outcome of efficacy (recurrence of febrile or non-febrile seizures) was reported in all tables at the following time
points: 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 or more months.
We determined the quality of the evidence by using the GRADE approach, where evidence was downgraded in the presence
of a high risk of bias in at least one study, indirectness of the evidence, unexplained heterogeneity or inconsistency,
imprecision of results, high probability of publication bias. Evidence is downgraded once if the limitation is considered to be
serious and twice if very serious.
Results 
Description of studies 
Results of the search
Among 86 articles identified as potentially relevant, 40 articles met the criteria for this review (see Characteristics of
included studies). Together, these 40 articles describe 30 randomised trials and their (long-term) follow-up. The details of the
other 46 studies are given in Characteristics of excluded studies.
Included studies
The interventions compared against placebo or no treatment included intermittent oral diazepam in four studies (Autret 1990;
Ramakrishnan 1986; Rosman 1993; Verrotti 2004) or rectal diazepam in five studies (Knudsen 1985; Mosquera 1987; 
Pavlidou 2006;Taghdiri 2011; Uhari 1995 [where a rectal dose was followed by oral doses for the time of the fever]),
continuous phenobarbitone in 10 studies (Bacon 1981; Camfield 1980; Farwell 1990; Heckmatt 1976; Mamelle 1984; 
McKinlay 1989; Ngwane 1980; Ramakrishnan 1986; Thilothammal 1993; Wolf 1977), intermittent phenobarbitone
in three studies (Mackintosh 1970; Ramakrishnan 1986; Wolf 1977), continuous oral phenytoin in one study (Bacon 1981
), continuous oral valproate in five studies (McKinlay 1989; Mamelle 1984; Mosquera 1987; Ngwane 1980; Williams 1979
), continuous oral pyridoxine in one study (McKiernan 1981), intermittent oral ibuprofen in one study (Van Stuijvenberg 1998
), intermittent oral clobazam in one study (Bajaj 2005); continuous zinc sulfate for six months in one study (Fallah 2015
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); and intermittent rectal diclofenac versus placebo followed after eight hours by either ibuprofen or acetaminophen
or placebo in one study (Strengell 2009). Other studies compared interventions against each other: continuous
phenobarbitone and intermittent diazepam in two studies (Garcia 1984; Salehiomran 2016); intermittent rectal
diazepam and intermittent rectal valproate in one study (Daugbjerg 1990); and a comparison between intermittent
oral diazepam and intermittent oral clobazam in two studies (Ghazavi 2016; Khosroshahi 2011).
These studies enrolled 4361 participants with febrile seizures among whom 4256 were used in the analysis of this
review. The number of participants analysed for each intervention (number of participants included in placebo trials
only) was as follows: diazepam 1476 (771); continuous phenobarbitone 1075 (494); intermittent phenobarbitone 341
(32); phenytoin 90 (90); valproate 303 (48); pyridoxine 107 (107); ibuprofen 230 (230); clobazam 60 (60); zinc sulfate
100 (100); diclofenac versus placebo followed after eight hours by ibuprofen, acetaminophen or placebo 231 (231);
continuous phenobarbitone versus diazepam 245; diazepam versus valproate 169; diazepam versus clobazam 143. It
should be noted that a number of these papers included a comparison of outcomes in placebo versus one of two
randomised seizure treatments (that is A versus C; B versus C). As no pooled analyses were done in which the effects
of different antiepileptic or antipyretic drugs were summarised and compared with (placebo) controls, we did not
introduce unit-of-analysis errors. Families withdrew from these studies for various reasons, including change of
residence, withdrawal of consent, and a variety of unacceptable adverse effects detailed in so far as was possible in
the additional table 'Unwanted medication effects' (Table 1).
Study outcomes included a comparison of observed and expected seizure recurrence frequency at time points
ranging between six and 48 months after randomisation, and in one case (Ramakrishnan 1986) at 60 to 72 months.
A brief description of the 30 original studies reported in the articles included in this review:
Autret 1990 was a study of 185 children, aged 8 to 36 months, after their first febrile seizure and with fewer than two risk1.
factors for recurrence. Interventions were intermittent oral diazepam (0.5 mg load and 0.2 mg/kg maintenance) or placebo.
Outcomes assessed were recurrent seizures at 12 months after randomisation and adverse medication effects during the
12 months of treatment.
Bacon 1981 reported a study involving 270 children following a first febrile seizure. There were three arms to this study.2.
Children were allocated either to treatment with continuous oral phenytoin 8 mg/kg/day, continuous phenobarbitone 5
mg/kg/day, or placebo and followed for assessment of recurrent seizures at 12 months after randomisation and adverse
medication effects during the 12 months of treatment.
Bajaj 2005 studied 60 children aged six months to five years presenting with one or more febrile seizures. Children were3.
allocated to intermittent oral clobazam (0.75 mg/kg body weight twice daily) or placebo during the course of fever and
followed for assessment of recurrent seizures at six months after randomisation and adverse medication effects during the
six months of treatment.
Camfield 1980 was a study of 79 children aged 6 to 36 months following a first febrile seizure. Children were allocated4.
either to treatment with continuous phenobarbitone 4 to 5 mg/kg/day or placebo (both groups treated with antipyretics)
and followed for assessment of recurrent seizures at 12 months after randomisation. In their second paper, the authors
assessed the adverse effects of phenobarbitone in toddlers, including behavioural and cognitive aspects, during the 12
months of treatment using the same cohort.
Daugbjerg 1990 studied 169 children following a first febrile seizure. Children were allocated either to intermittent rectal5.
diazepam (5 mg for those younger than three years or 7.5 mg for those three years or over) or intermittent valproate
suppositories (150 mg for those weighing less than 10 kg or 300 mg for those weighing 10 kg of more). They were
followed for assessment of recurrent seizures at six and 12 months after randomisation and adverse medication effects
during 12 months of treatment.
Fallah 2015 was a randomised single-blind clinical study comparing zinc sulfate with placebo. One hundred children, aged6.
1½ to 5 years, with a first simple febrile seizure, with weight and height above the third percentile and with normal serum
zinc levels, were randomised to either daily zinc sulfate 2 mg/kg (maximum 50 mg) for six consecutive months or to
placebo. Authors assessed seizure recurrence at 12 months and unwanted effects.
Farwell 1990 was a study of 217 children following a first febrile seizure and who had at least one risk factor for7.
recurrence. They were allocated either to treatment with continuous phenobarbitone 4 to 5 mg/kg/day or placebo, and
followed for assessment of recurrent seizures at 6, 12, 18, and 24 months after randomisation; and adverse medication
effects after 24 months of treatment. Sleep disturbances were reported in a second paper and late cognitive effects of
phenobarbital for this study in a third publication.
Garcia 1984 studied 100 children aged six to 60 months following a first febrile seizure (simple or complex) with random8.
allocation either to intermittent rectal diazepam (0.5 mg/kg/dose eight-hourly for the duration of the fever) or continuous
phenobarbitone (5 mg/kg/day) plus antipyretics for both group. Children were followed for assessment of recurrent
seizures at 18 months after randomisation and adverse medication effects during these 18 months of treatment.
Ghazavi 2016 was an open-label trial that randomised children (six to 60 months of age) who presented with at least one9.
simple febrile seizure. They were treated with either oral diazepam 0.33 mg/kg every eight hours for two days or oral
clobazam for two days dosed by participant's weight (daily 5 mg when weight ≤ 5 kg, twice daily 5 mg when 6 to 10 kg,
twice daily 7.5 mg when 11 to 15 kg, and twice daily 10 mg when > 15 kg). In a follow-up period of 12 months, authors
assessed seizure recurrence and adverse effects.
Heckmatt 1976 was a study of 165 children with a mean age of 20 months following a first febrile seizure. They were10.
allocated either to treatment with continuous phenobarbitone 4 to 5 mg/kg/day or no treatment. The children were followed
for assessment of recurrent seizures at six months after randomisation and adverse medication effects during the six
months of treatment.
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Khosroshahi 2011 studied 80 children aged six months to five years who had had one or more simple febrile seizures.11.
They were allocated either to intermittent oral diazepam (0.33 mg/kg/ dose every eight hours for two days) or intermittent
oral clobazam for two days with the following dosages: 5 mg daily in children up to 5 kg; 5 mg twice daily in children six to
10 kg; 7.5 mg twice daily in children 11 to 15 kg; and 10 mg twice daily in children > 15 kg. Children were followed for
assessment of recurrent seizures at 12 months after randomisation, and adverse medication effects during these 12
months of treatment.
Knudsen 1985 reported on a single study of 289 children following their first febrile seizure, allocated either to intermittent12.
rectal diazepam (5 mg for children less than three years or 7.5 mg for those aged over three years) compared to no
treatment. They were followed for assessment of recurrent seizures at 6, 12, and 18 months after randomisation and
adverse medication effects during 18 months of treatment.
Mackintosh 1970 was a study of 32 children aged six to 16 months who had had a first febrile seizure. They were13.
allocated either to intermittent phenobarbitone at 30 mg with acetyl acetic acid 150 mg or placebo and followed for
assessment of recurrent seizures at six and 12 months after randomisation; adverse medication effects were not
addressed.
Mamelle 1984 reported on one study of 69 children aged six to 48 months following a first febrile seizure (excluding those14.
with focal seizures or neuropsychiatric disorders). These were allocated either to treatment with continuous
phenobarbitone 3 to 4 mg/kg/day, continuous oral valproate 30 to 40 mg/kg/day, or placebo, and followed for assessment
of recurrent seizures at 18 months after randomisation; adverse medication effects were not addressed.
McKiernan 1981 studied 107 children aged six to 52 months who had had a first or second febrile seizure. Children in the15.
active treatment arm received continuous oral pyridoxine (in two doses of 20 mg) or placebo. They were followed for
assessment of recurrent seizures for 12 months after randomisation. We used estimates from the reported Kaplan Meier
curves to assess recurrent seizures at six and 12 months. Adverse medication effects were not addressed.
McKinlay 1989 was a study of 151 children aged six to 72 months who had had at least one previous febrile seizure or a16.
complicated febrile seizure. There were three arms to this study. Children were allocated either to treatment with
continuous phenobarbitone 5 mg/kg/day, continuous oral valproate 30 mg/kg/day or no treatment and followed for
assessment of recurrent seizures at 6, 12, and 24 months after randomisation, and adverse medication effects during the
24 months of treatment.
Mosquera 1987 studied 69 children following a first febrile seizure and allocated to intermittent rectal diazepam 0.517.
mg/kg/dose, continuous oral valproate 30 mg/kg/day or no treatment. Children were followed for assessment of recurrent
seizures at 6, 12, and 24 months after randomisation; adverse medication effects were not addressed.
Ngwane 1980 was a study of 64 children aged six to 18 months following a first febrile seizure. There were three arms to18.
this study with allocation either to phenobarbitone 3 to 6 mg/kg/day or valproate 30 to 60 mg/kg/day. Patients that were
eligible but not included were consider the control group receiving no treatment. Children were followed for a mean of 12
months after randomisation to assess recurrent seizures and adverse medication effects.
Pavlidou 2006 studied 139 children aged six to 36 months that were randomly assigned in a prospective controlled trial to19.
receive either intermittent prophylaxis with rectal diazepam or no prophylaxis. The children were followed for assessment
of recurrent seizures at 6, 12, and 36 months after randomisation and adverse medication effects during 36 months of
treatment.
Ramakrishnan 1986 studied 120 children aged two to 72 months following a first febrile seizure. These children were20.
allocated to continuous phenobarbitone 3 to 5 mg/kg/day, intermittent phenobarbitone in the same dosage, intermittent
oral diazepam 0.6 mg/kg/day or no treatment. They were followed for assessment of recurrent seizures at 60 to 72
months after randomisation and adverse medication effects during the period of treatment.
Rosman 1993 studied 406 children aged six to 60 months who had had at least one febrile seizure. The interventions21.
were intermittent oral diazepam 1 mg/kg/day or placebo. Outcomes were recurrent seizures and adverse treatment effects
during 24 months of treatment. We used estimates from the reported Kaplan Meier curves to assess recurrent seizures at
6, 12, and 24 months.
Salehiomran 2016 studied 145 children (six to 60 months of age) with ≥ 3 simple febrile seizures or with complex febrile22.
seizure in a randomised controlled trial. Included participants were either treated with continuous phenobarbitone 3 to 5
mg/kg/day in two doses for at least a year, or intermittent oral diazepam 0.33 mg/kg/ three times a day for two days at
each febrile episode. Seizure recurrence was assessed at 12 months, as were adverse effects.
Strengell 2009 was a study of 231 children aged four months to four years who had had a first febrile seizure. All febrile23.
episodes during follow-up were treated first with either intermittent rectal diclofenac or placebo. After eight hours,
treatment was continued with oral ibuprofen 5 mg/kg up to four times a day, oral acetaminophen 10 mg/kg up to four times
a day, or placebo. Children were followed for assessment of recurrent seizures. We used estimates from the reported
Kaplan Meier curves to assess recurrent seizures at 6, 12, 18, and 24 months. Adverse medication effects were not
addressed.
Taghdiri 2011 studied 80 children, aged nine months to five years after their first febrile seizure, and treated them with24.
either rectal diazepam (0.5 mg/kg) combined with acetaminophen or acetaminophen only. Children were followed for 12
months for assessment of recurrence.
Thilothammal 1993 studied 60 children aged six to 72 months following a first febrile seizure and allocated either to25.
treatment with continuous phenobarbitone 5 mg/kg/day or placebo. An additional 30 children with an atypical seizure were
not randomised but treated with phenobarbitone (not included in our analyses). The children were then followed for
assessment of recurrent seizures at six and 12 months and for adverse medication effects after six and 12 months of
treatment.
Uhari 1995 studied 180 children following a first febrile seizure and allocated to intermittent rectal followed by intermittent26.
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oral diazepam 0.6 mg/kg or placebo. Both groups were treated with antipyretics for the duration of the fever. They were
followed for assessment of recurrent seizures and adverse medication effects for 24 months. Kaplan Meier curves were
used to assess recurrence at six and 12 months.
Van Stuijvenberg 1998 studied 230 children aged 12 to 48 months who had a febrile seizure and at least one risk factor27.
for recurrence. Children were allocated either to intermittent oral Ibuprofen 5 mg/kg/day or placebo and followed for
assessment of recurrent seizures during 24 months after randomisation. We used estimates from the reported Kaplan
Meier curves to assess recurrent seizures at 6, 12, and 24 months after randomisation; adverse medication effects were
not addressed.
Verrotti 2004 studied 110 children aged six months to five years with one simple febrile seizure; 45 children were28.
'randomly' allocated to treatment with intermittent oral diazepam (0.35 mg/kg every eight hours) during each episode of
fever higher than 38.8 °C, continuing until the child had been afebrile for 24 hours; and 65 children were allocated to a
group with no treatment. They were followed for assessment of recurrent seizures at 48 months after randomisation and
adverse medication effects during the 48 months of treatment. We used estimates from the reported Kaplan Meier curves
to assess recurrent seizures at 6, 12, and 24 months after randomisation.
Williams 1979 studied 58 children aged six to 72 months after two or more simple febrile seizures. Children in the active29.
treatment group were allocated to continuous oral valproate 40 mg/kg/day and were compared with children on no
treatment. They were followed for assessment of recurrent seizures and adverse medication effects at 12 months after
randomisation.
Wolf 1977 was a study of 355 children aged six to 48 months who had had a first febrile seizure. There were three arms to30.
this study. Children were allocated either to continuous phenobarbitone 3 to 4 mg/kg/day, intermittent phenobarbitone 5
mg/kg/day or no treatment. They were followed for assessment of recurrent seizures for a median of 28 months after
randomisation and adverse medication effects during 24 months of treatment. We used estimates from the reported
Kaplan Meier curves to assess recurrent seizures at 6, 12, and 24 months after randomisation. In a following paper, the
authors reported behaviour disturbances and the long-term effect of phenobarbital on cognitive function.
Excluded studies
We excluded all studies which were not RCTs. Some trials confined the analysis to participants completing the trial period
free of unwanted effects, in which case we had no access to the outcome of those who stopped treatment early when they
could not tolerate it. As we felt that the lack of intention-to-treat data introduced an important potential for bias, we excluded
these trials. One trial of antipyretics did not address the central issue of febrile seizure recurrence but researched the
question of effect on temperature, and was also excluded.
Risk of bias in included studies 
Allocation (selection bias)
Satisfactory allocation concealment was noted in 10 of the 30 included studies (Autret 1990; Fallah 2015; Farwell 1990; 
Mackintosh 1970; McKiernan 1981; Rosman 1993; Strengell 2009; Uhari 1995; Van Stuijvenberg 1998; Verrotti 2004
); no concealment was attempted in 13 of the 30 included studies (Daugbjerg 1990; Garcia 1984; Heckmatt 1976; 
Khosroshahi 2011; Knudsen 1985; Mamelle 1984; McKinlay 1989; Mosquera 1987; Ngwane 1980; Pavlidou 2006; Taghdiri
2011; Williams 1979; Wolf 1977), which used a method of quasi-randomisation. In the remainder of the studies the method
of allocation concealment, if any, was unclear.
Blinding (performance bias and detection bias)
Eleven studies were double-blinded (Autret 1990; Bajaj 2005; Camfield 1980; Farwell 1990; Mackintosh 1970; McKiernan
1981; Rosman 1993; Strengell 2009; Thilothammal 1993; Uhari 1995; Van Stuijvenberg 1998); two studies were
single-blinded (Fallah 2015; Mamelle 1984); and there was no blinding in 17 studies (Bacon 1981; Daugbjerg 1990; Garcia
1984; Ghazavi 2016; Heckmatt 1976; Khosroshahi 2011; Knudsen 1985; McKinlay 1989; Mosquera 1987; Ngwane 1980; 
Pavlidou 2006; Ramakrishnan 1986; Salehiomran 2016; Taghdiri 2011; Verrotti 2004; Williams 1979; Wolf 1977).
Incomplete outcome data (attrition bias)
In many studies the data analysis did not include all enrolled participants as follows: Autret 1990: nine of 185 included
children were lost in the analyses - six on diazepam, three on placebo; Bacon 1981: 69 of 270 enrolled participants lost -
unsure of group allocation but study groups similar in size - i.e. 48 on phenobarbitone, 47 on phenytoin and 43 on placebo
with no recurrences in any to the time of withdrawal; Camfield 1980: two of 79 lost - one on phenobarbitone, one on placebo;
Daugbjerg 1990: two withdrawn and four in each group lost to follow-up; Farwell 1990: 26 of 217 lost - 10 on phenobarbitone
and 16 on placebo; Heckmatt 1976: four of 165 lost - two on phenobarbitone, two on no treatment; Khosroshahi 2011: eight
of 80 lost – five on clobazam and three on diazepam; Knudsen 1985: 16 of 289 lost - five on diazepam and 11 on no
treatment; Mamelle 1984: four of 69 lost - one on valproate, two on phenobarbitone and one on placebo; Mosquera 1987:
four of 69 lost - all four on placebo. It must be noted that most of the included studies were undertaken 20 to 30 years ago,
since when the rigour of conducting and reporting RCTs has improved. We attempted to contact study authors to obtain IPD,
but without success.
Selective reporting (reporting bias)
Protocols were not available for any of the included trials. We made a judgement of the risk of bias based on the information
included in the publications (see Characteristics of included studies and 'Summary of findings' tables for more information).
Other potential sources of bias
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Study population sizes varied from 32 to 406. These were associated with numbers in one treatment arm ranging
from 16 (Mackintosh 1970) up to 204 (Rosman 1993). The smaller studies were prone to distortion of treatment effect
because of the small numbers of participants.
Publication bias
Four of the 38 analyses included results from more than five trials (Analysis 1.1, Analysis 1.2, Analysis 2.1, Analysis 2.2). For
these analyses, we assessed publication bias with funnel plots. We did not find evidence of publication bias for Analysis 1.1, 
Analysis 1.2 and Analysis 2.1 (Figure 1, Figure 2 and Figure 3), but we did find evidence of publication bias for Analysis 2.2
(asymmetry indicated in Figure 4). There were too few studies to comment on whether there was publication bias for the
other comparisons.
Effects of interventions 
We describe the results of 13 comparisons, followed by a description of the recurrence risk of febrile seizures in the non-
intervention groups and the occurrence of adverse medication effects.
1. Intermittent oral or rectal diazepam versus placebo or no treatment (see Analysis 1.1; Analysis 1.2; Analysis 1.3; Analysis
1.4; Analysis 1.5; Analysis 1.6; Analysis 1.7)
Nine trials compared oral or rectal diazepam versus placebo or no treatment. (Autret 1990; Knudsen 1985; Mosquera 1987; 
Pavlidou 2006 Ramakrishnan 1986; Rosman 1993; Taghdiri 2011; Uhari 1995; Verrotti 2004).
In three trials (Autret 1990; Rosman 1993; Uhari 1995) the control group received placebos and in the remaining six the
controls received no treatment. Most trials assessed recurrence at 6 (6 trials), 12 (8 trials) and 24 months (4 trials),
recurrence at 18, 36, 48 and 60 to 72 was only assessed by one trial each.
All trials included participants with a first febrile seizure (FS), except Rosman 1993 (≥ 1 FS) and Taghdiri 2011 (all
FSs), and some included only participants with simple febrile seizures (Autret 1990; Verrotti 2004). This analysis contains
two treatment subgroups (diazepam given orally or rectally), but within each subgroup some treatment differences existed.
First, the oral diazepam subgroup: In Autret 1990 diazepam was administered in a 0.5 mg/kg load with a maintenance dose
during the febrile period of 0.2 mg/kg/day. Rosman 1993 used a slightly higher dose, of 1 mg/kg/day. Verrotti 2004 used 0.35
mg/kg every eight hours during each episode of fever higher than 38.8 °C, continuing until the child had been afebrile for 24
hours. Ramakrishnan 1986 used oral diazepam 0.2 mg/kg three times daily for the duration of the fever. Second, the rectal
diazepam subgroup: differences existed in the way the doses were calculated (either based on age or weight) and the
interval and duration of the dosing. Knudsen 1985 was the only study using an age-based dosing scheme (5 mg for age
above 3 years and 7.5 mg for older children) with intervals of 12 hours during fever. Mosquera 1987 and Taghdiri 2011 used
0.5 mg/kg every eight hours during fever, while Pavlidou 2006 used 0.33 mg/kg every eight hours on first day and every 12
hours on the following days. Uhari 1995 started with a first rectal dose (2.5 mg for < 7 kg, 5 mg 7 to 15 kg and 10 mg > 15
kg) followed after six hours by oral diazepam 0.2 mg/kg every eight hours during fever with a maximum of two days.
There were significant overall findings at 6, 12, 18, 24, 36 and 48 months, not at 60 to 72 months: At six months, 65 (11.4%)
of 570 treated children had a recurrence compared with 104 (17.9%) of 581 children in the control group (Risk Ratio (RR)
0.64, 95% CI 0.48 to 0.85); NNT 16, Analysis 1.1. At 12 months, 123 (17.5%) of 703 treated children had a recurrence
compared with 181 (25.4%) of 713 children in the control group (RR 0.69, 95% CI 0.56 to 0.84); NNT 13, Analysis 1.2. At 18
months, 19 (12.5%) of 152 treated children had a recurrence compared with 46 (33.6%) of 137 children in the control group
(RR 0.37, 95% CI 0.23 to 0.60); NNT 5, Analysis 1.3. At 24 months, 72 (20.3%) of 355 treated children had a recurrence
compared with 105 (27.3%) of 384 in the control group (RR 0.73, 95% CI 0.56 to 0.95); NNT 15, Analysis 1.4. At 36 months,
24 (54.5%) of 44 treated children had a recurrence compared with 43 (60.6%) of 71 children in the control group (RR 0.58,
95% CI 0.40 to 0.85); NNT 4, Analysis 1.5. At 48 months, 5 (11.1%) of 45 treated children had a recurrence compared with
20 (30.8%) of 65 in the control group (RR 0.36, 95% CI 0.15 to 0.89); NNT 6, Analysis 1.6. At 60 to 72 months, none (0%) of
30 treated children had a recurrence compared with 6 (20.0%) of 30 in the control group (RR 0.08, 95% CI 0.00 to 1.31);
NNT 5, Analysis 1.7.
Subgroup analyses did not always yield significant results when the overall analyses did. Oral diazepam did not reach
significance at six months, and rectal diazepam was not significantly different at 24 months.
2. Continuous phenobarbitone versus placebo or no treatment (see Analysis 2.1; Analysis 2.2; Analysis 2.3; Analysis 2.4; 
Analysis 2.5; Analysis 2.6).
Ten trials compared continuous phenobarbitone versus placebo or no treatment. (Bacon 1981; Camfield 1980; Farwell 1990;
Garcia 1984; Heckmatt 1976; Mamelle 1984; McKinlay 1989; Ngwane 1980; Thilothammal 1993; Wolf 1977).
In five trials (Bacon 1981; Camfield 1980; Farwell 1990; Mamelle 1984; Thilothammal 1993) the control group received
placebos and in the remaining five the controls received no treatment. Most trials assessed recurrence at 6 months (6 trials)
and 12 months (7 trials), while recurrence at 18, 24 and 60 to 72 was assessed in 2, 3 and 1 trials respectively. Behavioural
changes were assessed by Camfield 1980 at 12 months.
All trials included participants with a first seizure, except McKinlay 1989 (> 1 FS or complicated FS) and Thilothammal 1993
(≥ 2); three included only participants with simple febrile seizures (Camfield 1980; Ngwane 1980; Thilothammal 1993
), and two included participants with complicated seizures (Farwell 1990: > 1 risk factor; McKinlay 1989: > 1 FS or
complicated FS). Initial dosing varied between 3 to 6 mg/kg. Some trials adjusted dosing based on drug levels
measured in saliva (Bacon 1981: 8 - 15 mg/L) or blood (Heckmatt 1976: 65 - 129 µmol/l; Mamelle 1984: > 60 µmol/l, Wolf
1977: 10 - 20 µg/ml). In the other trials dosing was not adjusted during follow-up.
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Continuous phenobarbitone resulted in significantly fewer recurrences at 6, 12 and 24 months, but not at 18 and 60 to 72
months. At six months, 43 (10.4%) of 412 treated children had a recurrence compared with 75 (17.8%) of 421 children in the
control group (RR 0.59, 95% CI 0.42 to 0.83); NNT 14, Analysis 2.1. At 12 months, 67 (17.0%) of 395 treated children had a
recurrence compared with 127 (30.8%) of 412 children in the control group (RR 0.55, 95% CI 0.42 to 0.70); NNT 8, Analysis
2.2. At 18 months, 43 (33.3%) of 129 treated children had a recurrence compared with 58 (43.0%) of 135 children in the
control group (RR 0.77, 95% CI 0.56 to 1.05); NNT 10, Analysis 2.3. At 24 months, 61 (23.9%) of 255 treated children had a
recurrence compared with 96 (34.5%) of 278 children in the control group (RR 0.69, 95% CI 0.53 to 0.89); NNT 10, Analysis
2.4. At 60 to 72 months, 9 (30.0%) of 30 treated children had a recurrence compared with 6 (20.0%) of 30 children in the
control group (RR 1.50, 95% CI 0.61 to 3.69); NNT 10, Analysis 2.5
3. Intermittent phenobarbitone versus placebo or no treatment (see Analysis 3.1; Analysis 3.2; Analysis 3.3; Analysis 3.4).
Three trials compared intermittent phenobarbitone versus placebo or no treatment (Mackintosh 1970; Ramakrishnan 1986; 
Wolf 1977).
In one trial (Mackintosh 1970) the control group received placebos and in the remaining two (Ramakrishnan 1986; Wolf
1977) the controls received no treatment. Recurrence was assessed at six and 12 months in two trials each, and at 24 and
60 to 72 months in one trial each.
All studies included children with a first febrile seizure, and in addition Mackintosh 1970 included only those with simple
seizures. Dosing schemes differed between trials. In Mackintosh 1970, participants received an initial dose of 60 mg,
followed by 30 mg every six hours for the duration of fever. Participants included in Ramakrishnan 1986 received 3 - 5
mg/kg/day divided into two doses, and participants included in Wolf 1977 received 5 mg/kg for the duration of fever, as well
as an initial 'load' of 30 mg/kg to a maximum of 120 mg.
Intermittent phenobarbitone did not lead to fewer recurrences at 6, 12, 24 and 60 to 72 months. At six months, 18 (11.5%) of
156 treated children had a recurrence compared with 11 (8.8%) of 125 children in the control group (RR 1.37, 95% CI 0.67 to
2.81); NNT 37, Analysis 3.1. At 12 months, 34 (21.8%) of 156 treated children had a recurrence compared with 27 (21.6%) of
125 children in the control group (RR 1.01, 95% CI 0.65 to 1.59); NNT 500, Analysis 3.2. At 24 months, 35 (25.0%) of 140
treated children had a recurrence compared with 32 (29.4%) of 109 children in the control group (RR 0.85, 95% CI 0.57 to
1.28); NNT 23, Analysis 3.3. At 60 to 72 months, 5 (16.7%) of 30 treated children had a recurrence compared with 6 (20.0%)
of 30 children in the control group (RR 0.83, 95% CI 0.28 to 2.44); NNT 31, Analysis 3.4.
4. Phenytoin versus placebo (see Analysis 4.1)
One trial compared phenytoin to placebo (Bacon 1981).
Of the children allocated to phenytoin treatment, 16 (34.0%) of 47 had a recurrence at 12 months compared to 15 (34.9%) of
the 43 in the placebo group (RR 0.98, 95% CI 0.55 to 1.73); NNT 112, Analysis 4.1.
5. Valproate versus placebo or no treatment (see Analysis 5.1; Analysis 5.2; Analysis 5.3; Analysis 5.4).
Two trials compared valproate versus placebo or no treatment (McKinlay 1989; Mosquera 1987).
McKinlay 1989 included 151 children with more than one febrile seizure or with complicated febrile seizures, and compared
valproate 30 mg/kg versus placebo, while Mosquera 1987 included 69 children with a first febrile seizure and treated with
valproate 30 mg/kg or no treatment.
Valproate only reduced recurrence at 18 months, but not at 6, 12 and 24 months. At 18 months, 1 (4.5%) of 22 children in the
active treatment group had a recurrence compared to 9 (34.6%) of 26 children in the control group (RR 0.13, 95% CI 0.02 to
0.96); NNT 4, Analysis 5.3. At six months, 10 (14.1%) of 71 children in the active treatment group had a recurrence
compared to 10 (11.8%) of 85 in the control group (RR 1.20, 95% CI 0.55 to 2.62); NNT 44, Analysis 5.1. At 12 months, 24
(19.8%) of 121 treated children had a recurrence compared with 32 (23.9%) of 134 children in the control group (RR 0.82,
95% CI 0.52 to 1.29); NNT 25, Analysis 5.2. At 24 months, 19 (26.8%) of 71 treated children had a recurrence compared with
18 (21.2%) of 85 children in the control group (RR 1.26, 95% CI 0.73 to 2.18); NNT 18, Analysis 5.4.
6. Pyridoxine versus placebo (see Analysis 6.1; Analysis 6.2).
McKiernan 1981 was the only study comparing pyridoxine with placebo.
At six months, 4 (7.3%) of 55 had a recurrence compared to 8 (15.4%) of 52 in the placebo group (RR 0.47, 95% CI 0.15 to
1.48); NNT 13, Analysis 6.1. At 12 months, 7 (12.7%) of 55 children in the active treatment group had a recurrence
compared to 10 (19.2%) of 52 in the placebo group (RR 0.66, 95% CI 0.27 to 1.61); NNT 16, Analysis 6.2.
7. Intermittent ibuprofen versus placebo (see Analysis 7.1; Analysis 7.2; Analysis 7.3).
Van Stuijvenberg 1998 was the only study comparing intermittent ibuprofen with placebo.
At six months, 26 (23.4%) of 111 children allocated to the active treatment group had a recurrence compared to 25 (21.0%)
of 119 allocated to the placebo group (RR 1.11, 95% CI 0.69 to 1.81); NNT 42, Analysis 7.1. At 12 months, 31 children
(27.9%) of 111 allocated to the active treatment group had a recurrent seizure compared to 35 (29.4%) of 119 allocated to
the placebo group (RR 0.95, 95% CI 0.63 to 1.43); NNT 67, Analysis 7.2. At 24 months, 36 (32.4%) of 111 children allocated
to the ibuprofen group had a recurrent seizure compared with 46 (38.7%) of 119 children allocated to the placebo group (RR
0.84, 95% CI 0.59 to 1.19); NNT 16, Analysis 7.3.
8. Intermittent clobazam versus placebo (see Analysis 8.1).
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Bajaj 2005 was the only study comparing clobazam with placebo.
At six months, 9 (30.0%) of 30 children allocated to the clobazam group had a seizure recurrence compared to 25 (83.3%) of
30 allocated to the placebo group (RR 0.36, 95% CI 0.20 to 0.64); NNT 2, Analysis 8.1.
9. Zinc sulfate versus placebo (see Analysis 9.1).
Fallah 2015 was the only study comparing zinc sulfate to placebo.
At 12 months, 11 (22.0%) of 50 children allocated to six months daily zinc sulfate treatment had a seizure recurrence
compared to 19 (38.0%) of 50 children allocated to placebo (RR 0.58, 95% CI 0.31 to 1.09), NNT 7, Analysis 9.1.
10. Diclofenac versus placebo followed, after eight hours, by ibuprofen, acetaminophen or placebo (see Analysis 10.1; 
Analysis 10.2; Analysis 10.3; Analysis 10.4).
Strengell 2009 randomised 231 children who had a first febrile seizure to receive either diclofenac (1.5 mg/kg) or placebo.
After eight hours, treatment was randomly continued with either ibuprofen, acetaminophen or placebo. Since outcomes were
unaffected by the second randomisation, we only consider the first in this meta-analysis. At six months, 14 (12.0%) of 117
children allocated to the diclofenac group had a seizure recurrence compared to 17 (14.9%) of 114 children allocated to the
placebo group (RR 0.80, 95% CI 0.42 to 1.55), NNT 25, Analysis 10.1. At 12 months, 19 (16.2%) of 117 children allocated to
the diclofenac group had a seizure recurrence compared to 27 (23.7%) of 114 children allocated to the placebo group (RR
0.69, 95% CI 0.40 to 1.16); NNT 14, Analysis 10.2. At 18 months, 23 (19.7%) of 117 children allocated to the diclofenac
group had a seizure recurrence compared to 31 (27.2%) of 114 children allocated to the placebo group (RR 0.72, 95% CI
0.45 to 1.16); NNT 14, Analysis 10.3. At 24 months, 26 (22.2%) of 117 children allocated to the diclofenac group had a
seizure recurrence compared to 32 (28.1%) of 114 children allocated to the placebo group (RR 0.79, 95% CI 0.51 to 1.24);
NNT 17, Analysis 10.4.
11. Phenobarbitone versus intermittent diazepam (see Analysis 11.1; Analysis 11.2).
Two studies compared phenobarbitone with intermittent diazepam (Garcia 1984, Salehiomran 2016).
At 12 months, 17 (23.0%) of 74 children treated with continuous phenobarbitone had a recurrence versus 11 (15.5%) of the
71 children treated with intermittent oral diazepam (RR 1.48, 95% CI 0.75 to 2.94); NNT 14, Analysis 11.1. At 18 months, 5
(10.0%) of 50 children allocated to the phenobarbitone group had a seizure recurrence compared to 4 (8.0%) of 50 children
allocated to the intermittent rectal diazepam group (RR 1.25, 95% CI 0.36 to 4.38); NNT 50, Analysis 11.2.
12. Intermittent rectal diazepam versus intermittent valproate (see Analysis 12.1; Analysis 12.2).
This comparison was examined in one study, Daugbjerg 1990.
At six months, 11 (12.4%) of 89 children allocated to intermittent rectal diazepam had a recurrent seizure compared to 7
(8.8%) of 80 children allocated to the valproate treatment group (RR 1.41, 95% CI 0.58 to 3.47); NNT 28, Analysis 12.1. At
12 months, 23 (25.8%) of 89 children allocated to the intermittent rectal diazepam group had a seizure recurrence compared
to 14 (17.5%) of 80 children allocated to the valproate group (RR 1.48, 95% CI 0.82 to 2.67); NNT 12, Analysis 12.2.
13. Intermittent diazepam versus intermittent clobazam (see Analysis 13.1).
Two studies compared intermittent diazepam with intermittent clobazam (Ghazavi 2016; Khosroshahi 2011). At 12 months, 3
(4.2%) of 71 children allocated to the clobazam group had a seizure recurrence compared to 7 (9.7%) of 72 allocated to the
diazepam group (RR 2.28 (95% CI 0.62 to 8.42), NNT 19, Analysis 13.1.
Recurrence risk of febrile seizures in the non-intervention groups
As a number of studies included children with risk factors known to be associated with a higher recurrence risk, the data on
this issue were skewed towards higher recurrence risk in the placebo or control groups. Nonetheless, viewing pooled data on
this issue allowed us to weigh the clinical importance of any significant results in the intervention arms of the studies. The
data are summarised below and in Figure 5.
Recurrence risk in control groups at six months: these pooled data included the studies of Bajaj 2005; Camfield 1980; 
Farwell 1990; Heckmatt 1976; Knudsen 1985; Mackintosh 1970; McKinlay 1989; McKiernan 1981; Mosquera 1987; Pavlidou
2006; Rosman 1993; Strengell 2009; Thilothammal 1993; Uhari 1995; Van Stuijvenberg 1998; Verrotti 2004; Wolf 1977. A
total of 259 (19.4%) of 1333 children had a recurrent febrile seizure within six months of study entry (placebo-controlled trials:
166/804 (20.6%); no-treatment controlled trials: 93/529 (17.6%)).
Recurrence risk at 12 months: pooled data at 12 months included the studies of Autret 1990; Bacon 1981; Camfield 1980; 
Fallah 2015; Farwell 1990; Knudsen 1985; Mackintosh 1970; McKiernan 1981; McKinlay 1989; Mosquera 1987; Ngwane
1980; Pavlidou 2006; Rosman 1993; Strengell 2009; Taghdiri 2011; Thilothammal 1993; Uhari 1995; Van Stuijvenberg 1998;
Verrotti 2004; Williams 1979; Wolf 1977. A total of 415 (26.7%) of 1554 children had a recurrent seizure at 12 months
(placebo-controlled trials: 262/1009 (26.0%); no-treatment controlled trials: 153/545 (28.1%)).
Recurrent risk at 18 months: pooled data included the studies of Farwell 1990; Knudsen 1985; Mamelle 1984; Strengell
2009. One hundred and thirty-five (35.0%) of 386 children in these studies had a recurrent seizure within 18 months
(placebo-controlled trials: 89/249 (35.7%); no-treatment controlled trials: 46/137 (33.6%)).
Risk of recurrence at 24 months: pooled data included the studies from Farwell 1990; McKinlay 1989; Mosquera 1987; 
Rosman 1993; Strengell 2009; Uhari 1995; Van Stuijvenberg 1998 ; Verrotti 2004; Wolf 1977. Two hundred and seventy-
nine (31.2%) of 895 children had a documented recurrent febrile seizure at 24 months (placebo-controlled trials: 210/636
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(33.0%); no-treatment controlled trials: 69/259 (26.6%)).
Risk of recurrence at 36 months: data included only Pavlidou 2006: 43 (60.5%) recurrences among 71 children receiving no
treatment.
Risk of recurrence at 48 months: only data from Verrotti 2004 were available; 20 (30.8%) of 65 children receiving no
treatment had a documented recurrent febrile seizure at 48 months.
Recurrent risk at 60 to 72 months: analysis included data from only one study (Ramakrishnan 1986); 6 (20.0%) of 30 children
receiving no treatment had a recurrent seizure at this point in time.
Treatment adherence
Fifteen of 30 trials assessed treatment adherence using various approaches. Their results are summarised in Table 1. Some
measures were relatively crude, e.g. Camfield 1980 reported the presence or absence of the drug in serum samples. Others,
e.g. Heckmatt 1976 and McKinlay 1989, measured drug levels on a random, ad hoc basis. There was no reported
consistency between the relationship of drug levels ascertained in this way and seizure control. This is in accordance with
current clinical practice, which recommends drug level measurement only when non-adherence is suspected; in such a
situation only the presence or absence of the drug is helpful. Our observations serve to emphasise the importance of
intention-to-treat analysis.
Adverse events and medication effects
Antiepileptic drugs are know for frequent and sometimes severe side effects in children. A variety of adverse effects were
reported in some studies. Some were described as “unacceptable” or as reasons for the child to stop medication and, in
some instances, to leave the trial. A descriptive summary, detailed in so far as was possible from the information provided in
the articles, is given in Table 2 'Unwanted medication effects'. We consider the fact that adverse effects were not addressed
at all in eight included studies and only in one arm of the study in a further two as a measure of the generally poor quality of
these studies.
Camfield 1980 was the only one to address behavioural change in a focused way. The authors recorded the incidence of
behavioural changes in those allocated to the active phenobarbitone treatment group, comparing them to those in the
placebo group, at 12-month follow-up. Fifteen of 35 (42.8%) allocated to phenobarbitone reported behavioural change or
sleep disturbance, compared to eight of 30 (26.3%) allocated to the placebo group (RR 1.61, 95% CI 0.79 to 3.26). More
detail on the adverse effects in this study is given in the summary table under 'adverse effects', see below.
Discussion 
Summary of main results
We note no significant benefit for intermittent phenobarbitone, phenytoin, valproate, pyridoxine, ibuprofen or zinc sulfate
versus placebo or no treatment; nor for diclofenac versus placebo followed by ibuprofen, acetaminophen or placebo; nor for
continuous phenobarbitone versus diazepam, intermittent rectal diazepam versus intermittent valproate, or oral diazepam
versus clobazam. There was a significant reduction of recurrent febrile seizure risk with intermittent diazepam versus placebo
or no treatment at all time points, except for 60 to 72 months, with a risk ratio (RR) ranging from 0.37 to 0.73 and a number
needed to treat (NNT) from 5 to 14 patients (rounded to integer). A significant reduction in febrile seizure recurrence risk was
also seen in continuous phenobarbitone versus placebo or no treatment in each meta-analyses that included three or more
trials (at 6, 12 and 24 months, but not at 18 and 60 to 72 months). Risk ratios ranged from 0.54 at 12 months to 0.69 at 24
months, with a NNT of 8 to 10.
Another significant reduction in febrile seizure recurrence was seen in the intermittent clobazam group compared to
placebo at six months follow-up: the risk ratio was 0.36, with a NNT of 2. However, with an extraordinarily high number
of recurrences in 25 out of 30 (83.3%) children in the control group, we feel the play of chance has most likely led to an
unrepeatable apparent beneficial effect for the treatment group. The median recurrence rate in the control groups of all
included trials was approximately 20% at six months (Figure 5), indicating how potentially misleading this study's findings are
likely to be.
As has been indicated, the recording of adverse effects in these studies was very variable and often non-existent. Camfield
1980 documented lower comprehension scores in phenobarbitone-treated children (yet with small numbers), which
correlated with length of phenobarbitone treatment. The findings were supported by the data of Farwell 1990. In general,
adverse effects were recorded in up to 30% of children in the phenobarbitone-treated group, although notably the studies by
Bacon 1981 and Camfield 1980 (the latter for behavioural change or sleep disturbance) observed no difference with control
groups. Knudsen 1985 noted mild transient adverse effects in up to 36% of children in the diazepam-treated groups.
Fallah 2015 offered a novel approach by evaluating the effect of zinc supplementation on febrile seizure recurrence risk.
Previous studies demonstrated blood and cerebrospinal fluid zinc levels to be significantly lower than in children with afebrile
seizures. Zinc level is known to stimulate pyridoxal kinase enzyme activity and the decarboxylation of glutamic acid, as well
as increasing brain gamma-amino-butyric acid (GABA) levels. Although it was hypothesised that decreased zinc levels might
play a role in the pathogenesis of febrile seizures supplementation in this study, it conferred no significant benefit over
placebo (RR 0.58, 95% CI 0.31 to 1.09).
Figure 5 offers useful data when counselling parents on the natural history of the condition. As one might predict, there was
no significant difference in recurrence rate in those treated with placebo or those who had no treatment. For each follow-up
epoch recurrence rates stay remarkably similar at between 20% and 35%, except for the remarkable 36-month follow-up rate
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in Pavlidou 2006 of 60.5%, an outlier unlikely to be repeated. This continuing risk serves to emphasise the importance of
conveying appropriate supportive advice to parents (see below).
In summary, we found reduced recurrence rates in children treated with intermittent diazepam or continuous phenobarbitone.
Both drugs lead to the advent of mild to moderate adverse effects in up to 30% of its recipients. However, since the long-term
outcome of children with febrile seizures is good, irrespective of whether their febrile seizures are successfully prevented or
not, only short-term benefits may be expected from treatment and they should be weighed against possible drug-related
adverse events. To emphasise the point we should bear in mind we would need to treat 100 children with either intermittent
diazepam or phenobarbitone to save up to 10 children from a recurrence, while giving 33 children unwanted effects. The
mainstay of intervention should be the provision of information for the families involved on recurrence risk, first aid
management and the benign nature of the phenomenon. Parents should be provided with contact details for medical services
so that they will feel supported in the event of a recurrence, which inevitably leads to anxiety and fright for the vast majority of
those involved.
Overall completeness and applicability of evidence
Completeness: The two interventions found to be effective in reducing future seizure recurrence were supported by nine
(intermittent diazepam) and 10 (continuous phenobarbitone) unique trials of predominantly low quality. The results of the
related meta-analyses were fairly consistently in favour of the intervention, more so for diazepam (for which there was only
one trial with results favouring control) than for phenobarbitone (which had two trials favouring control). The majority of these
trials included children after their first simple febrile seizure. Thus there is reasonable evidence to conclude their
effectiveness to prevent a recurrent seizure in this population with a NNT ranging from 5 to 14.
Applicability: All studies concern the population at risk of recurrent febrile seizures, and evaluate commonly-used medical
interventions. Knudsen 1991 have indicated that the long-term outcome of children with febrile seizures is good, irrespective
of whether their febrile seizures are successfully prevented or not. His early observations on the benign nature of the
phenomenon for most children is in keeping with common experience in clinical practice and the opinion cited in standard
texts. No additional long-term benefit can therefore be expected in addition to the reduced risk of recurrence for both
intermittent diazepam and continuous phenobarbitone. This benefit should be weighed against the clear risk of adverse
events. Hence the decision to treat must rest on whether quality of life and shorter-term morbidity may be altered by the use
of drugs.
Quality of the evidence
Most of the reviewed trials date from 20 or more years ago and are of a methodological quality which nowadays would be
recognised as needing improvement. Methods of randomisation and allocation concealment often do not meet current
standards, and treatment versus no treatment is more commonly seen than treatment versus placebo, leading to obvious
sources of bias. Nonetheless, the size of the data pool does allow us to draw some conclusions about the value of
intervention with medication for this common childhood phenomenon.
Potential biases in the review process
The review authors worked closely together at each step of the review, double-checking each other's assessments. We
found that the methodological quality of most of the antiepileptic drug studies was very low, low or moderate. The 'Risk of
bias' tables identify examples of selection, performance and detection, attrition, and reporting bias. Publication bias is also
likely, as shown in the present analysis. We contacted all UK neurologists and selected North American colleagues before
the original review to assess this risk. They were asked to declare if they knew of any studies unpublished for showing a lack
of treatment effect. None came forward with an example.
Agreements and disagreements with other studies or reviews
We are not aware of any other current review, or that our review findings and conclusion contradict those of any other review
published more than 20 years ago.
Authors' conclusions 
Implications for practice 
There were some significant results, although no clinically important benefits, for the management of children with febrile
seizures for intermittent diazepam and continuous phenobarbitone. No benefit was demonstrated for phenytoin, valproate,
pyridoxine, intermittent phenobarbitone or antipyretics in the form of intermittent ibuprofen, acetaminophen or diclofenac in
the management of febrile seizures. Intermittent clobazam conferred some benefit at six months follow-up but the result may
be difficult to replicate. Zinc supplementation offered no benefit. Parents should be supported with adequate contact details
of medical services and information on recurrence, first aid management and, most importantly, the benign nature of the
phenomenon.
Implications for research 
If future studies are to be considered, then due attention should be given to the quality of randomisation allocation and
concealment with placebo as a control. Adverse effects should be recorded systematically for both intervention and control
groups. However, given the long-term benign nature of the phenomenon of febrile seizures and the relatively higher rate of
reporting of adverse effects to date, unless a significant case of justification can be made it seems difficult to justify further
research in this area.
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Differences between protocol and review 
In a post-hoc change from protocol, in line with current Cochrane recommendations, we report 13 Summary of Findings
tables; one for each comparison in the review.
Published notes 
Characteristics of studies
Characteristics of included studies 
Autret 1990
Methods Double-blind RCT
 
Participants 185, age 8 - 36 months, first FS, < 2 RF
 
Interventions Intermittent oral diazepam, 0.5 mg load, 0.2 mg maintenance per kilo, or placebo
 
Outcomes RS @ 12 months, adverse effects @ 12 months
 
Notes Attrition: 6 diazepam, 3 placebo; results presented as participant days; significant
hyperactivity in diazepam group; 1 SUDEP in placebo group
 
Risk of bias table
Bias Authors' judgement Support for judgement
Allocation concealment (selection
bias)
Low risk Centralised allocation
 
Blinding (performance bias and
detection bias)
Low risk Double-blind
 
Incomplete outcome data (attrition
bias)
Low risk 9 (6 Diazepam, 3 Placebo) of 185 withdrawn
 
Selective reporting (reporting bias) Low risk Stated outcome objective met
 
Other bias Low risk No bias identified
 
Blinding of participants and
personnel (performance bias)
Low risk Double-blind
 
Blinding of outcome assessment
(detection bias)
Low risk Double-blind
 
Bacon 1981
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Methods RCT
 
Participants 207, after first FS
 
Interventions Phenytoin, 8 mg per kilo, or phenobarbitone 5 mg per kilo, or placebo
 
Outcomes RS @ 12 months, adverse effects
 
Notes Attrition 69
 
Risk of bias table
Bias Authors'judgement Support for judgement
Allocation concealment (selection
bias)
Unclear risk Allocation methodology and concealment not discussed in
publication.
 
Blinding (performance bias and
detection bias)
High risk Outcome rater blinded, doctor not blinded
 
Incomplete outcome data (attrition
bias)
High risk 45 lost: 12 moved; 5 behaviour; 5 epilepsy; 2 rash = 69 of 207
 
Selective reporting (reporting bias) Low risk Stated outcome objective met
 
Other bias Low risk No bias identified
 
Blinding of participants and
personnel (performance bias)
High risk Outcome rater blinded, doctor not blinded
 
Blinding of outcome assessment
(detection bias)
High risk Outcome rater blinded, doctor not blinded
 
Bajaj 2005
Methods Double-blind RCT
 
Participants 60 children aged 6 months to 5 years
 
Interventions Clobazam (0.75 mg/kg body weight twice daily) or placebo, during the course of fever
 
Outcomes Seizure recurrence at 6 months
 
Notes  
Risk of bias table
8 Prophylactic drug management for febrile seizures in children
16 / 65
Bias Authors'judgement Support for judgement
Allocation concealment (selection
bias)
Unclear risk Double-blind design, not stated how
 
Blinding (performance bias and
detection bias)
Unclear risk Not stated
 
Incomplete outcome data (attrition
bias)
Unclear risk “Sixty patients who completed the study duration of six months were
only considered”, unclear out of how many patients originally
 
Selective reporting (reporting bias) Low risk Stated outcome objective met
 
Other bias Low risk No bias identified
 
Blinding of participants and
personnel (performance bias)
Unclear risk Not stated
 
Blinding of outcome assessment
(detection bias)
Unclear risk Not stated
 
Camfield 1980
Methods Double-blind RCT
 
Participants 79, 6 - 36 months, first simple FS
 
Interventions Phenobarbitone 4 - 5 mg per kilo, or placebo, both with antipyretics
 
Outcomes RS @ 6 months, RS @ 12 months, behavioural changes @ 12 months
 
Notes Attrition: 2, 1 from each group
 
Risk of bias table
Bias Authors' judgement Support for judgement
Allocation concealment (selection
bias)
Unclear risk Not stated how
 
Blinding (performance bias and
detection bias)
Low risk Special placebo manufactured
 
Incomplete outcome data (attrition
bias)
Low risk 12 of 79 lost; 4 with side effects but data collected on 10 of these
 
Selective reporting (reporting bias) Low risk Stated outcome objective met
 
Other bias Low risk No bias identified
 
Blinding of participants and
personnel (performance bias)
Low risk  
Blinding of outcome assessment
(detection bias)
Low risk  
Daugbjerg 1990
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Methods RCT, open label
 
Participants 169, first FS
 
Interventions Rectal diazepam 5 mg for < 3 yrs; 7.5 mg for 3 or over; or valproate suppository 150
mg for < 10 kg or 300 mg for 10 kg or more
 
Outcomes RS @ 6 months, 12 months, adverse effects
 
Notes 2 withdrawn, 4 lost during follow-up
 
Risk of bias table
Bias Authors' judgement Support for judgement
Allocation concealment (selection
bias)
High risk Odd/even dates - no concealment
 
Blinding (performance bias and
detection bias)
High risk No blinding (selection bias)
 
Incomplete outcome data (attrition
bias)
Low risk 6 of 169 withdrawn; 4 lost to follow-up in each group
 
Selective reporting (reporting bias) Low risk Stated outcome objective met
 
Other bias Low risk No bias identified
 
Blinding of participants and
personnel (performance bias)
High risk No blinding
 
Blinding of outcome assessment
(detection bias)
High risk No blinding
 
Fallah 2015
Methods Single-centre randomised single-blind clinical study
 
Participants Children aged 1½ - 5 years, with first simple FS, with weight and height above the third
percentile and with normal serum zinc level
 
Interventions Group 1: Daily zinc sulfate 2 mg/kg (maximum 50 mg) for 6 consecutive months
Group 2: Placebo
 
Outcomes Seizure recurrence at 12 months, side effects
 
Notes  
Risk of bias table
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Bias Authors'judgement Support for judgement
Allocation concealment (selection
bias)
Low risk Computer-generated equal simple randomisation
 
Blinding (performance bias and
detection bias)
Low risk Single-blind design
 
Incomplete outcome data (attrition
bias)
Low risk No loss to follow-up, no exclusions
 
Selective reporting (reporting bias) High risk Recurrence data at 3, 6 and 9 months not given. Kaplan Meijer method
used to report results, no absolute numbers.
 
Other bias Low risk No bias identified
 
Blinding of participants and
personnel (performance bias)
Unclear risk Randomisation and blinding was done by an investigator with no clinical
involvement in the trial. Data collectors, outcome assessors and data
analysts were all kept blinded to the allocation
 
Blinding of outcome assessment
(detection bias)
Low risk Randomisation and blinding was done by an investigator with no clinical
involvement in the trial. Data collectors, outcome assessors and data
analysts were all kept blinded to the allocation
 
Farwell 1990
Methods Double-blind RCT
 
Participants 217, first FS, > 1 RF
 
Interventions Phenobarbitone 4 - 5 mg per kilo, or placebo
 
Outcomes RS @ 6 months, RS @ 12 months, RS @ 18 months, RS @ 24 months. IQ after 2 and
3 - 5 years, sleep disturbances
 
Notes Attrition 26, 10 PB, 16 placebo
 
Risk of bias table
Bias Authors'judgement Support for judgement
Allocation concealment (selection
bias)
Low risk Adequate concealment using minimisation methodology as described
by Pocok and Simon
 
Blinding (performance bias and
detection bias)
Low risk Placebo control, blinding maintained with fake phenobarb levels
 
Incomplete outcome data (attrition
bias)
Low risk 86% of placebo, 77% phenobarb completed
 
Selective reporting (reporting bias) Low risk Stated outcome objective met
 
Other bias Low risk No bias identified
 
Blinding of participants and
personnel (performance bias)
Low risk Blinding maintained with fake phenobarb levels
 
Blinding of outcome assessment
(detection bias)
Low risk Blinding maintained with fake phenobarb levels
 
Garcia 1984
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Methods RCT
 
Participants 100. 6 - 60 months, first FS
 
Interventions During fever: either rectal diazepam 0.5 mg/kg/dose x 8-hourly or phenobarbitone 5
mg/kg/day plus antipyretics for both groups
 
Outcomes RS @ 18 months; adverse effects
 
Notes No attrition
 
Risk of bias table
Bias Authors' judgement Support for judgement
Allocation concealment (selection
bias)
High risk None
 
Blinding (performance bias and
detection bias)
High risk None
 
Incomplete outcome data (attrition
bias)
Unclear risk No attrition
 
Selective reporting (reporting bias) Low risk Stated outcome objective met
 
Other bias Low risk No bias identified
 
Blinding of participants and
personnel (performance bias)
High risk None
 
Blinding of outcome assessment
(detection bias)
High risk None
 
Ghazavi 2016
Methods Single-centre randomised open-label trial
 
Participants Children 6 - 60 months of age with at least 1 simple FS
 
Interventions Oral diazepam 0.33 mg/kg every 8 hours for 2 days or oral clobazam for 2 days dosed
by patient's weight (daily 5 mg when weight ≤ 5 kg, twice daily 5 mg when 6 - 10 kg,
twice daily 7.5 mg when 11 - 15 kg, and twice daily 10 mg when > 15 kg)
 
Outcomes RS @ 12 months and adverse effects
 
Notes  
Risk of bias table
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Bias Authors' judgement Support for judgement
Allocation concealment (selection
bias)
High risk Randomisation methodology not mentioned
 
Blinding (performance bias and
detection bias)
High risk No blinding
 
Incomplete outcome data (attrition
bias)
High risk Not discussed
 
Selective reporting (reporting bias) Unclear risk  
Other bias Low risk No bias identified
 
Blinding of participants and
personnel (performance bias)
High risk No blinding
 
Blinding of outcome assessment
(detection bias)
High risk No blinding
 
Heckmatt 1976
Methods Quasi-RCT
 
Participants 165, first FS, mean age 20 months
 
Interventions Phenobarbitone 4 - 5 per kilo, or no treatment
 
Outcomes RS @ 6 months
 
Notes Attrition 4, 2 per arm, unblinded study
 
Risk of bias table
Bias Authors' judgement Support for judgement
Allocation concealment (selection
bias)
High risk Alternate day allocation
 
Blinding (performance bias and
detection bias)
High risk None
 
Incomplete outcome data (attrition
bias)
Low risk 4 of 165 lost but 39 of 88 stopped treatment
 
Selective reporting (reporting bias) Low risk Stated outcome objective met
 
Other bias Low risk No bias identified
 
Blinding of participants and
personnel (performance bias)
High risk None
 
Blinding of outcome assessment
(detection bias)
High risk None
 
Khosroshahi 2011
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Methods RCT
 
Participants 80 children, 1 or more simple febrile seizures
 
Interventions Oral diazepam 0.33 mg/kg/ dose every 8 hours for 2 days or oral clobazam for 2 days
with the following dosage: 5 mg, daily in children ≤ 5 kg; 5 mg twice daily in children 6
– 10 kg; 7.5 mg, twice daily in children 11 – 15 kg; and 10 mg, twice daily in children >
15 kg
 
Outcomes Recurrent seizures at 12 months
 
Notes Attrition 5 in clobazam group and 3 in diazepam group.
 
Risk of bias table
Bias Authors'judgement Support for judgement
Allocation concealment (selection
bias)
High risk Method of allocation not stated.
 
Blinding (performance bias and
detection bias)
High risk Not stated
 
Incomplete outcome data (attrition
bias)
Unclear risk 8 (10%) attrition. Clobazam: lost to follow-up (n = 5). Poor compliance (n
= 2). Change drug by other physician (n = 2). Repeated seizure without
fever (n = 1). Diazepam: lost to follow up (n = 3). Poor compliance (n = 1).
Prolonged use of drug (n = 1). Inaccessible (n = 1)
 
Selective reporting (reporting bias) Low risk Stated outcome objective met
 
Other bias Low risk No bias identified
 
Blinding of participants and
personnel (performance bias)
High risk None
 
Blinding of outcome assessment
(detection bias)
High risk None
 
Knudsen 1985
Methods Quasi-RCT
 
Participants 289, first FS
 
Interventions Intermittent rectal diazepam 5 for children < 3 years, 7.5 for > 3 years, or no treatment
 
Outcomes RS @ 6 months, RS @ 12 months, RS @ 18 months
 
Notes Attrition 16, 5 diazepam and 11 no treatment
 
Risk of bias table
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Bias Authors' judgement Support for judgement
Allocation concealment (selection
bias)
High risk Odd/even date allocation
 
Blinding (performance bias and
detection bias)
High risk None
 
Incomplete outcome data (attrition
bias)
Low risk 16 of 289 excluded – parents demanded treatment change
 
Selective reporting (reporting bias) Low risk Stated outcome objective met
 
Other bias Low risk No bias identified
 
Blinding of participants and
personnel (performance bias)
High risk None
 
Blinding of outcome assessment
(detection bias)
High risk None
 
Mackintosh 1970
Methods Double-blind RCT
 
Participants 32, 6 - 60 months, first simple FS
 
Interventions Phenobarbitone 30 with ASA 150, or placebo
 
Outcomes RS @ 6 months, RS @ 12 months
 
Notes Histogram used in estimations of recurrence risks
 
Risk of bias table
Bias Authors'judgement Support for judgement
Allocation concealment (selection
bias)
Low risk Adequate. "The child was allocated randomly to either treatment or
control group and neither the physician nor the mother knew to which
group the child had been allocated".
 
Blinding (performance bias and
detection bias)
Low risk Double-blind
 
Incomplete outcome data (attrition
bias)
Low risk Length of follow-up differed
 
Selective reporting (reporting bias) Low risk Stated outcome objective met
 
Other bias Low risk No bias identified
 
Blinding of participants and
personnel (performance bias)
Low risk Double-blind
 
Blinding of outcome assessment
(detection bias)
Low risk Double-blind
 
Mamelle 1984
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Methods Single-blind RCT
 
Participants 69, 6 - 48 months, first FS, excluded focal and neuropsychiatric disorders
 
Interventions Phenobarbitone 3 - 4 per kilo, or valproate 30 - 40 per kilo, or placebo
 
Outcomes RS @ 18 months, length of follow-up differed (mean > 20 months)
 
Notes Attrition: 4
 
Risk of bias table
Bias Authors' judgement Support for judgement
Allocation concealment (selection
bias)
High risk Not used
 
Blinding (performance bias and
detection bias)
High risk Unblinded
 
Incomplete outcome data (attrition
bias)
Low risk 4 of 69 dropped out
 
Selective reporting (reporting bias) Low risk Stated outcome objective met
 
Other bias Low risk No bias identified
 
Blinding of participants and
personnel (performance bias)
High risk Unblinded
 
Blinding of outcome assessment
(detection bias)
High risk Unblinded
 
McKiernan 1981
Methods Double-blind RCT
 
Participants 107, 6 - 52 months, first or second FS
 
Interventions Pyridoxine 2 times 20 mg, or placebo
 
Outcomes RS @ 6 months, RS @ 12 months
 
Notes Kaplan Meier used in estimations
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Allocation concealment (selection
bias)
Low risk Adequate. "Neither the investigators nor the parents were aware of
which vitamin the children were receiving."
 
Blinding (performance bias and
detection bias)
Low risk Participants and investigator blinded, pharmacist unblinded
 
Incomplete outcome data (attrition
bias)
High risk 80 of 107 completed 6 months
 
Selective reporting (reporting bias) Low risk Stated outcome objective met
 
Other bias Low risk No bias identified
 
Blinding of participants and
personnel (performance bias)
Low risk Participants and investigator blinded, pharmacist unblinded
 
Blinding of outcome assessment
(detection bias)
Low risk Participants and investigator blinded, pharmacist unblinded
 
McKinlay 1989
Methods Quasi-RCT
 
Participants 151, 6 - 72 months, > one previous FS, or complicated FS
 
Interventions Phenobarbitone 5 per kilo, or valproate 30 per kilo, or no treatment
 
Outcomes RS @ 6 months, RS @ 12 months, RS @ 24 months
 
Notes  
Risk of bias table
Bias Authors' judgement Support for judgement
Allocation concealment (selection
bias)
High risk Alternate participants allocated
 
Blinding (performance bias and
detection bias)
High risk None
 
Incomplete outcome data (attrition
bias)
Low risk 24 (13%) lost to follow-up
 
Selective reporting (reporting bias) Low risk Stated outcome objective met
 
Other bias Low risk No bias identified
 
Blinding of participants and
personnel (performance bias)
High risk None
 
Blinding of outcome assessment
(detection bias)
High risk None
 
Mosquera 1987
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Methods RCT
 
Participants 69, first FS
 
Interventions Intermittent rectal diazepam 0.5 mg/kg every 8 hours during fever, valproate 30 per
kilo, or no treatment
 
Outcomes RS @ 6 months, RS @ 12 months, RS @ 24 months
 
Notes Attrition: 4 from the control group unaccounted for
 
Risk of bias table
Bias Authors' judgement Support for judgement
Allocation concealment (selection
bias)
High risk Allocation concealment not discussed in the publication
 
Blinding (performance bias and
detection bias)
High risk Open label, no blinding
 
Incomplete outcome data (attrition
bias)
Low risk Seemingly no attrition
 
Selective reporting (reporting bias) Low risk Stated outcome objective met
 
Other bias Low risk No bias identified
 
Blinding of participants and
personnel (performance bias)
High risk Open label, no blinding
 
Blinding of outcome assessment
(detection bias)
High risk Open label, no blinding
 
Ngwane 1980
Methods Quasi-RCT, included were randomised in the 2 treatment arms, the participants that
refused or were otherwise not included but eligible were considered the ‘nothing arm’
 
Participants 64, 6 - 18 months, first simple FS
 
Interventions Phenobarbitone 3 - 6 per kilo, or valproate 30 - 60 per kilo, or no treatment
 
Outcomes RS @ 12 months, adverse effects
 
Notes  
Risk of bias table
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Bias Authors'judgement Support for judgement
Allocation concealment (selection
bias)
High risk Although the physicians were blinded to the 2 interventions, no
randomisation nor blinding was used for the ‘no treatment’ control
group.
 
Blinding (performance bias and
detection bias)
High risk Although the physicians were blinded to the 2 interventions, no
randomisation nor blinding was used for the ‘no treatment’ control
group.
 
Incomplete outcome data (attrition
bias)
Low risk 4 of 43 in trial withdrew due to side effects
 
Selective reporting (reporting bias) Low risk Stated outcome objective met
 
Other bias Low risk No bias identified
 
Blinding of participants and
personnel (performance bias)
High risk Although the physicians were blinded to the 2 interventions, no
randomisation nor blinding was used for the ‘no treatment’ control
group.
 
Blinding of outcome assessment
(detection bias)
High risk Although the physicians were blinded to the 2 interventions, no
randomisation nor blinding was used for the ‘no treatment’ control
group.
 
Pavlidou 2006
Methods RCT
 
Participants 139 children aged 6 to 36 months; first febrile seizure
 
Interventions Rectal diazepam 0.33 mg/kg 8-hourly first day and then 12-hourly second day versus
no prophylaxis (checked!)
 
Outcomes Recurrent seizures 6 months, 12 months and 3 years
 
Notes 6 children lost to follow-up
 
Risk of bias table
Bias Authors' judgement Support for judgement
Allocation concealment (selection
bias)
High risk Quasi-random, alternate day allocation to intervention groups.
 
Blinding (performance bias and
detection bias)
High risk No blinding
 
Incomplete outcome data (attrition
bias)
Low risk Attrition of 6 of 145
 
Selective reporting (reporting bias) Low risk Stated outcome objective met
 
Other bias Low risk No bias identified
 
Blinding of participants and
personnel (performance bias)
High risk No blinding
 
Blinding of outcome assessment
(detection bias)
High risk No blinding
 
Ramakrishnan 1986
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Methods RCT
 
Participants 120, 2 - 72 months, first FS
 
Interventions Phenobarbitone 3 - 5 per kilo, or intermittent phenobarbitone same dose, or
intermittent diazepam 0.6 per kilo, or no treatment
 
Outcomes RS @ 60 - 72 months
 
Notes No attrition reported, unblinded study
 
Risk of bias table
Bias Authors' judgement Support for judgement
Allocation concealment (selection
bias)
Unclear risk Not used, “Randomly divided in 4 groups of 30 each”
 
Blinding (performance bias and
detection bias)
High risk No blinding
 
Incomplete outcome data (attrition
bias)
Low risk Apparently no withdrawal
 
Selective reporting (reporting bias) Low risk Stated outcome objective met
 
Other bias Low risk No bias identified
 
Blinding of participants and
personnel (performance bias)
High risk No blinding
 
Blinding of outcome assessment
(detection bias)
High risk No blinding
 
Rosman 1993
Methods Double-blind RCT
 
Participants 406, 6 - 60 months, at least 1 FS
 
Interventions Intermittent oral diazepam 1 per kilo per day, or placebo
 
Outcomes RS @ 6 months, RS @ 12 months, RS @ 24 months
 
Notes Kaplan Meier used in estimations
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Allocation concealment (selection
bias)
Low risk Adequate. "Only the pharmacist and the biostatisticians knew the
details of the randomisation schedule."
 
Blinding (performance bias and
detection bias)
Low risk Manufactured placebo
 
Incomplete outcome data (attrition
bias)
Low risk 29 (12 diazepam. 17 placebo) of 406 withdrew due to side effects or
frequent recurrence
 
Selective reporting (reporting bias) Low risk Stated outcome objective met
 
Other bias Low risk No bias identified
 
Blinding of participants and
personnel (performance bias)
Low risk Adequate. "Only the pharmacist and the biostatisticians knew the
details of the randomisation schedule."
 
Blinding of outcome assessment
(detection bias)
Low risk Adequate. "Only the pharmacist and the biostatisticians knew the
details of the randomisation schedule."
 
Salehiomran 2016
Methods Single-centre RCT
 
Participants Children 6 - 60 months of age with ≥ 3 simple FS or with complex FS
 
Interventions Continuous phenobarbitone 3 - 5 mg/kg/day in 2 doses for at least a year, or
intermittent oral diazepam 0.33 mg/kg/3 times a day for 2 days
 
Outcomes RS @ 12 months, adverse effects
 
Notes  
Risk of bias table
Bias Authors'judgement Support for judgement
Allocation concealment (selection
bias)
High risk Randomisation methodology not mentioned
 
Blinding (performance bias and
detection bias)
High risk No blinding
 
Incomplete outcome data (attrition
bias)
Unclear risk 9 participants excluded based on exclusion criteria. Loss to follow-up
not discussed
 
Selective reporting (reporting bias) Unclear risk  
Other bias Low risk No bias identified
 
Blinding of participants and
personnel (performance bias)
High risk No blinding
 
Blinding of outcome assessment
(detection bias)
High risk No blinding
 
Strengell 2009
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Methods Randomised, placebo-controlled, double-blind trial
 
Participants 231, 4 - 48 months, first febrile seizure; 63 of these had had a complicated first seizure
 
Interventions Random allocation first into 2 groups (rectal diclofenac (1.5 mg/kg suppository) versus
placebo) and then to 3 groups (oral placebo versus acetaminophen (15 mg/kg) versus
ibuprofen (10 mg/kg)) - each up to four times per day for as long as temp. > 38 °C
 
Outcomes Actuarial analysis of seizure recurrence up to 24 months
 
Notes Participants included in analyses for as long as they participated because Kaplan
Meier used with no imputations for the dropouts
 
Risk of bias table
Bias Authors'judgement Support for judgement
Allocation concealment (selection
bias)
High risk Open random allocation schedule. "The allocation sequence for rectal
medications was generated by two of the authors (M.U. and H.R.) by the
use of random-number tables. The allocation was performed as a block
randomization with permuted blocks with a block size of 4."
 
Blinding (performance bias and
detection bias)
Low risk Special preparations made for drugs/placebos by pharmaceutical
companies
 
Incomplete outcome data (attrition
bias)
High risk Attrition: 50 of 231: 231 randomised: 34 did not want to continue; 9 lost; 7
others dropped out for a variety of reasons
 
Selective reporting (reporting bias) Low risk Stated outcome objective met
 
Other bias Low risk No bias identified
 
Blinding of participants and
personnel (performance bias)
Low risk Special preparations made for drugs/placebos by pharmaceutical
companies
 
Blinding of outcome assessment
(detection bias)
Low risk Special preparations made for drugs/placebos by pharmaceutical
companies
 
Taghdiri 2011
Methods Quasi-RCT
 
Participants 80 children, aged 9 months to 5 years, simple seizure
 
Interventions Rectal diazepam (0.5 mg/kg) and acetaminophen versus acetaminophen only
 
Outcomes RS @ 12 months
 
Notes Letter to the editor, brief study description
 
Risk of bias table
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Bias Authors' judgement Support for judgement
Allocation concealment (selection
bias)
High risk Not used
 
Blinding (performance bias and
detection bias)
High risk Not blinded
 
Incomplete outcome data (attrition
bias)
Low risk  
Selective reporting (reporting bias) Unclear risk  
Other bias Low risk  
Blinding of participants and
personnel (performance bias)
High risk Not blinded
 
Blinding of outcome assessment
(detection bias)
High risk Not blinded
 
Thilothammal 1993
Methods Double-blind RCT
 
Participants 90 but only 60 used in randomisation, 6 - 72 months, 2 or more simple seizure, 60
simple FS (30 placebo, 30 phenobarbitone), 30 atypical (phenobarbitone)
 
Interventions Phenobarbitone 5 per kilo, or placebo
 
Outcomes RS @ 6 months, RS @ 12 months
 
Notes No attrition
 
Risk of bias table
Bias Authors'judgement Support for judgement
Allocation concealment (selection
bias)
Unclear risk Not stated
 
Blinding (performance bias and
detection bias)
Low risk Adequate placebo
 
Incomplete outcome data (attrition
bias)
Low risk Only 4 dropouts
 
Selective reporting (reporting bias) Low risk Stated outcome objective met
 
Other bias Low risk No bias identified
 
Blinding of participants and
personnel (performance bias)
Low risk Adequate placebo
 
Blinding of outcome assessment
(detection bias)
Low risk Adequate placebo. "The assessment of recurrence, side-effects and
compliance were done by one investigator who was blind to the type of
treatment throughout the study period.
 
Uhari 1995
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Methods Double-blind RCT
 
Participants 180, first FS
 
Interventions Intermittent rectal followed by oral diazepam, 0.6 per kilo, or placebo, both with
antipyretics
 
Outcomes RS @ 6 months, RS @ 12 months, RS @ 24 months
 
Notes Kaplan Meier used in estimations at 6 and 12 months
 
Risk of bias table
Bias Authors'judgement Support for judgement
Allocation concealment (selection
bias)
Low risk Adequate. "Only the statistician knew the details of the
randomization schedule."
 
Blinding (performance bias and
detection bias)
Low risk Not clearly stated, but claiming to be 'double blind' and using a
placebo
 
Incomplete outcome data (attrition
bias)
Low risk 19 of 180 withdrew
 
Selective reporting (reporting bias) Low risk Stated outcome objective met
 
Other bias Low risk No bias identified
 
Blinding of participants and
personnel (performance bias)
Low risk Not clearly stated, but claiming to be 'double blind' and using a
placebo
 
Blinding of outcome assessment
(detection bias)
Unclear risk Not clearly stated. Unknown if person assessing outcomes was
blinded.
 
Van Stuijvenberg 1998
Methods Double-blind RCT
 
Participants 230, 12 - 48 months, FS at least 1 risk factor
 
Interventions Intermittent oral ibuprofen 5 per kilo per day, or placebo
 
Outcomes RS @ 6 months, RS @ 12 months, RS @ 24 months
 
Notes Kaplan Meier used in estimations
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Allocation concealment (selection
bias)
Low risk Computer-generated randomization schedule, stratified by center. "Only
the biostatistician and the hospital pharmacists knew the actual
treatment allocation."
 
Blinding (performance bias and
detection bias)
Low risk Double-blinded
 
Incomplete outcome data (attrition
bias)
Low risk 23 of 230 without outcome data
 
Selective reporting (reporting bias) Low risk Stated outcome objective met
 
Other bias Low risk No bias identified
 
Blinding of participants and
personnel (performance bias)
Low risk Double-blinded
 
Blinding of outcome assessment
(detection bias)
Low risk Double-blinded
 
Verrotti 2004
Methods RCT
 
Participants 110, 6 - 60 months, 1 simple febrile seizure, no risk factors
 
Interventions Oral with diazepam, 0.35 mg/kg every 8 hours, during each episode of fever higher
than 38 °C, continuing until child afebrile for 24 hours or no treatment
 
Outcomes RS @ 6 months, RS @ 12 months, RS @ 24 months and RS @ 48 months
 
Notes Kaplan Meier used in estimations at months 6, 12 and 24
 
Risk of bias table
Bias Authors'judgement Support for judgement
Allocation concealment (selection
bias)
Low risk A statistician randomly assigned each child to Group A or B and the
doctors who followed these children did not know the randomisation
 
Blinding (performance bias and
detection bias)
High risk No blinding, open-label treatment vs no treatment.
 
Incomplete outcome data (attrition
bias)
Low risk Data available on 110 of 113 children, yet 45 intervention children are
compared to 65 controls
 
Selective reporting (reporting bias) Low risk Stated outcome objective met
 
Other bias Low risk No bias identified
 
Blinding of participants and
personnel (performance bias)
High risk None, open-label treatment vs no treatment.
 
Blinding of outcome assessment
(detection bias)
High risk None, open-label treatment vs no treatment.
 
Williams 1979
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Methods RCT
 
Participants 58, 6 - 72 months, 2 or more simple FS
 
Interventions Valproate 40 per kilo, or no treatment
 
Outcomes RS @ 12 months
 
Notes  
Risk of bias table
Bias Authors' judgement Support for judgement
Allocation concealment (selection
bias)
High risk Not used
 
Blinding (performance bias and
detection bias)
High risk None
 
Incomplete outcome data (attrition
bias)
Low risk No attrition
 
Selective reporting (reporting bias) Low risk Stated outcome objective met
 
Other bias Low risk No bias identified
 
Blinding of participants and
personnel (performance bias)
High risk  
Blinding of outcome assessment
(detection bias)
High risk None
 
Wolf 1977
Methods Quasi-RCT
 
Participants 355, 6 - 48 months, first FS
 
Interventions Phenobarbitone 3 - 4 per kilo, or intermittent phenobarbitone 5 per kilo, or no
treatment
 
Outcomes RS @ 6 months, RS @ 12 months, RS @ 24 months, late cognition and behaviour,
and adverse effects
 
Notes Kaplan Meier used in estimations. Duration of follow-up differed: 28 (6 - 70) months
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Allocation concealment (selection
bias)
High risk Not used. children were randomly assigned according to the last digit
of the chart number
 
Blinding (performance bias and
detection bias)
High risk None
 
Incomplete outcome data (attrition
bias)
Low risk Study design with actuarial analysis gave little attrition
 
Selective reporting (reporting bias) Low risk Stated outcome objective met
 
Other bias Low risk No bias identified
 
Blinding of participants and
personnel (performance bias)
High risk None
 
Blinding of outcome assessment
(detection bias)
High risk None
 
Footnotes
FS: febrile seizure
RCT: randomised controlled trial
RF: risk factor
RS: recurrent seizure
SUDEP: sudden unexpected death in epilepsy
Characteristics of excluded studies 
Addy 1977
Reason for exclusion Abstract only.
 
Antony 1983
Reason for exclusion 72 children randomised, 36 to phenobarbital and 36 to carbamazepine, but 32 not
included in final analysis. In 15 there was no follow-up, 5 were excluded because of
low or no anti-epileptic drug level, 9 excluded because of unacceptable adverse
effects, 2 had afebrile seizures and 1 child was incorrectly entered. Unfortunately no
follow-up detail is given for any of these 32 children (44%!).
 
Frehlih 1997
Reason for exclusion No data reported to estimate the occurrence of any of the prespecified outcomes.
 
Galli 1977
Reason for exclusion Could not get hold of a copy of paper.
 
Kazemi 2013
Reason for exclusion Publishes in Iranian
 
Knudsen 1978
Reason for exclusion Further exclusions from analysis 16 children in phenobarbitone group due to adverse
effects or parents' "dislike to it". No follow-up data given for these 16 (+ 24 lost to
follow-up) children.
 
Lahat 2000
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Reason for exclusion Not a recurrence study - acute treatment only.
 
Minagawa 1981
Reason for exclusion Not randomised, unclear allocation, with different numbers of participants per group,
the only randomisation was in 15 children to measure drug levels. Outside scope of
this review.
 
Rose 2005
Reason for exclusion RCT but with inadequate follow-up range of 0 - 14 months; data interpretation at 6
months impossible.
 
Rosman 2001
Reason for exclusion Research question asking parental experiences.
 
Shimazaki 1997
Reason for exclusion Not randomised, unclear allocation, different numbers of participants per group.
 
Steardo 1980
Reason for exclusion Not randomised, unclear allocation, different numbers of participants per group.
 
Van Esch 1995
Reason for exclusion Research question on effect on temperature, not on recurrences.
 
Vining 1987
Reason for exclusion Side effects study not on FC children.
 
Winsley 2005
Reason for exclusion No data reported to estimate the occurrence of any of the prespecified outcomes.
 
Footnotes
Characteristics of studies awaiting classification 
Footnotes
Characteristics of ongoing studies 
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Study name A randomised, multicentre, controlled trial of prophylactic use of diazepam for
recurrence of febrile seizures during a single febrile episode
 
Methods Multicentre open-label dose-comparing RCT
 
Participants Children with a simple febrile seizure
 
Interventions (1) Single dose of diazepam 0.5 mg/kg, or (2) 2 sequential doses of diazepam 0.5
mg/kg with 8 hours interval, or (3) diazepam 0.3 mg/kg/dose 3 times a day during
febrile period (terminated after confirmation that fever-free status maintains at least 24
hours)
 
Outcomes Febrile seizure recurrence, adverse events
 
Starting date 2010/09/29
 
Contact information Yoshihiko Morikawa (masaru_miura@tmhp.jp )
 
Notes  
Footnotes
Summary of findings tables
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Intermittent oral or rectal diazepam compared to placebo or no treatment for febrile seizures in children
Patient or population: Children with febrile seizures
Setting: Outpatients
Intervention: Intermittent oral or rectal diazepam
Comparison: placebo or no treatment
Outcomes Anticipated absolute effects* (95% CI) Relative
effect
(95% CI)
№ of
participants
(studies)
Quality of the
evidence
(GRADE)
Comments
Risk with placebo
or no treatment
Risk with Intermittent oral
or rectal diazepam
Recurrent seizure at 6
months
179 per 1,000 115 per 1,000
(86 to 152)
RR 0.64
(0.48 to
0.85)
1151
(6 RCTs)
⊕⊕⊕⊝
Moderate1
 
Recurrent seizure at 12
months
254 per 1,000 175 per 1,000
(142 to 213)
RR 0.69
(0.56 to
0.84)
1416
(8 RCTs)
⊕⊕⊕⊝
Moderate1
 
Recurrent seizure at 18
months
336 per 1,000 124 per 1,000
(77 to 201)
RR 0.37
(0.23 to
0.60)
289
(1 RCT)
⊕⊕⊝⊝
Low2
 
Recurrent seizure at 24
months
273 per 1,000 200 per 1,000
(153 to 260)
RR 0.73
(0.56 to
0.95)
739
(4 RCTs)
⊕⊕⊕⊕
High
 
Recurrent seizure at 36
months
606 per 1,000 351 per 1,000
(242 to 515)
RR 0.58
(0.40 to
0.85)
139
(1 RCT)
⊕⊕⊝⊝
Low2
 
Recurrent seizure at 48
months
308 per 1,000 111 per 1,000
(46 to 274)
RR 0.36
(0.15 to
0.89)
110
(1 RCT)
⊕⊕⊕⊝
Moderate3
 
Recurrent seizure at 60
months or greater
200 per 1,000 16 per 1,000
(0 to 262)
RR 0.08
(0.00 to
1.31)
60
(1 RCT)
⊕⊝⊝⊝
Very low2,4
 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk (the event rate in the
control group) and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of
the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate
of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different
from the estimate of effect
Footnotes
1 Downgraded once due to risk of bias: some of the RCTs contributing evidence had unsatisfactory allocation concealment
and blinding.
2 Downgraded twice due to serious risk of bias: the single RCT contributing evidence had unsatisfactory allocation
concealment and no blinding.
3 Downgraded once due to risk of bias: the single RCT contributing evidence had no blinding.
4 Downgraded once due to imprecision: relative effect has very large conf idence interval.
2 Continuous phenobarbitone compared to placebo or no treatment for febrile seizures in children
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Continuous phenobarbitone compared to placebo or no treatment for febrile seizures in children
Patient or population: Children with febrile seizures
Setting: Outpatients
Intervention: Continuous phenobarbitone
Comparison: placebo or no treatment
Outcomes Anticipated absolute effects* (95% CI) Relative
effect
(95% CI)
№ of
participants
(studies)
Quality of the
evidence
(GRADE)
Comments
Risk with placebo or
no treatment
Risk with Continuous
phenobarbitone
Recurrent seizure at 6
months
178 per 1,000 105 per 1,000
(75 to 148)
RR 0.59
(0.42 to
0.83)
833
(6 RCTs)
⊕⊕⊕⊝
Moderate1
 
Recurrent seizure at 12
months
308 per 1,000 166 per 1,000
(129 to 216)
RR 0.54
(0.42 to
0.70)
807
(7 RCTs)
⊕⊕⊝⊝
Low1,2
 
Recurrent seizure at 18
months
430 per 1,000 331 per 1,000
(241 to 451)
RR 0.77
(0.56 to
1.05)
264
(2 RCTs)
⊕⊕⊕⊝
Moderate1
 
Recurrent seizure at 24
months
345 per 1,000 238 per 1,000
(183 to 307)
RR 0.69
(0.53 to
0.89)
533
(3 RCTs)
⊕⊕⊕⊝
Moderate1
 
Recurrent seizure at 36
months Not reported NA
 
Recurrent seizure at 48
months Not reported NA
 
Recurrent seizure at 60
months or greater
200 per 1,000 300 per 1,000
(122 to 738)
RR 1.50
(0.61 to
3.69)
60
(1 RCT)
⊕⊝⊝⊝
Very low3,4
 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk (the event rate in the
control group) and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; NA: Not applicable; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of
the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate
of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different
from the estimate of effect
Footnotes
1 Downgraded once due to risk of bias: some of the RCTs contributing evidence had unsatisfactory allocation concealment
and blinding.
2 Downgraded once due to potential reporting bias: Funnel plot analysis detected risk of publication bias.
3 Downgraded twice due to serious risk of bias: the single RCT contributing evidence had unsatisfactory allocation
concealment and no blinding.
4 Downgraded once due to imprecision: relative effect has very large conf idence interval.
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Intermittent phenobarbitone compared to placebo or no treatment for febrile seizures in children
Patient or population: Children with febrile seizures
Setting: Outpatients
Intervention: Intermittent phenobarbitone
Comparison: placebo or no treatment
Outcomes Anticipated absolute effects* (95% CI) Relative
effect
(95% CI)
№ of
participants
(studies)
Quality of the
evidence
(GRADE)
Comments
Risk with placebo or
no treatment
Risk with Intermittent
phenobarbitone
Recurrent seizure at 6
months
88 per 1,000 121 per 1,000
(59 to 247)
RR 1.37
(0.67 to
2.81)
281
(2 RCTs)
⊕⊝⊝⊝
Very Low1,2,3
 
Recurrent seizure at 12
months
216 per 1,000 218 per 1,000
(140 to 343)
RR 1.01
(0.65 to
1.59)
281
(2 RCTs)
⊕⊕⊕⊝
Moderate1
 
Recurrent seizure at 18
months Not reported NA
 
Recurrent seizure at 24
months
294 per 1,000 250 per 1,000
(167 to 376)
RR 0.85
(0.57 to
1.28)
249
(1 RCT)
⊕⊕⊝⊝
Low4
 
Recurrent seizure at 36
months Not reported NA
 
Recurrent seizure at 48
months Not reported NA
 
Recurrent seizure at 60
months or greater
200 per 1,000 166 per 1,000
(56 to 488)
RR 0.83
(0.28 to
2.44)
60
(1 RCT)
⊕⊝⊝⊝
Very low3,4
 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk (the event rate in the
control group) and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; NA: Not applicable; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of
the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate
of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different
from the estimate of effect
Footnotes
1 Downgraded once due to risk of bias: some of the RCTs contributing evidence had unsatisfactory allocation concealment
and blinding.
2 Downgraded once due to inconsistency: trials had opposite effect sizes.
3 Downgraded once due to imprecision: relative effect has very large conf idence interval.
4 Downgraded twice due to serious risk of bias: the single RCT contributing evidence had unsatisfactory allocation
concealment and no blinding.
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Continuous oral phenytoin compared to placebo for febrile seizures in children
Patient or population: Children with febrile seizures
Setting: Outpatients
Intervention: Continuous oral phenytoin
Comparison: placebo
Outcomes Anticipated absolute effects* (95% CI) Relative
effect
(95% CI)
№ of
participants
(studies)
Quality of the
evidence
(GRADE)
Comments
Risk with
placebo
Risk with Continuous
oral phenytoin
Recurrent seizure at 6
months Not reported NA
 
Recurrent seizure at 12
months
349 per
1,000
342 per 1,000
(192 to 603)
RR 0.98
(0.55 to
1.73)
90
(1 RCT)
⊕⊕⊝⊝
Low1
 
Recurrent seizure at 18
months Not reported NA
 
Recurrent seizure at 24
months Not reported NA
 
Recurrent seizure at 36
months Not reported NA
 
Recurrent seizure at 48
months Not reported NA
 
Recurrent seizure at 60
months or greater Not reported NA
 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk (the event rate in the
control group) and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; NA: Not applicable; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of
the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate
of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different
from the estimate of effect
Footnotes
1 Downgraded twice due to serious risk of bias: the single RCT contributing evidence had unsatisfactory allocation
concealment and no blinding.
5 Continuous oral valproate compared to placebo or no treatment for febrile seizures in children
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Continuous oral valproate compared to placebo or no treatment for febrile seizures in children
Patient or population: Children with febrile seizures
Setting: Outpatients
Intervention: Continuous oral valproate
Comparison: placebo or no treatment
Outcomes Anticipated absolute effects* (95% CI) Relative
effect
(95% CI)
№ of
participants
(studies)
Quality of the
evidence
(GRADE)
Comments
Risk with placebo or
no treatment
Risk with Continuous
oral valproate
Recurrent seizure at 6
months
118 per 1,000 141 per 1,000
(65 to 308)
RR 1.20
(0.55 to
2.62)
156
(2 RCTs)
⊕⊕⊝⊝
Low1
 
Recurrent seizure at 12
months
239 per 1,000 196 per 1,000
(124 to 308)
RR 0.82
(0.52 to
1.29)
255
(4 RCTs)
⊕⊕⊝⊝
Low1
 
Recurrent seizure at 18
months
346 per 1,000 45 per 1,000
(7 to 332)
RR 0.13
(0.02 to
0.96)
48
(1 RCT)
⊕⊝⊝⊝
Very low1,2
 
Recurrent seizure at 24
months
212 per 1,000 267 per 1,000
(155 to 462)
RR 1.26
(0.73 to
2.18)
156
(2 RCTs)
⊕⊕⊝⊝
Low1
 
Recurrent seizure at 36
months Not reported NA
 
Recurrent seizure at 48
months Not reported NA
 
Recurrent seizure at 60
months or greater Not reported NA
 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk (the event rate in the
control group) and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; NA: Not applicable; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of
the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate
of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different
from the estimate of effect
Footnotes
1 Downgraded twice due to serious risk of bias: the single RCT contributing evidence had unsatisfactory allocation
concealment and no blinding.
2 Downgraded once due to imprecision: relative effect has very large conf idence interval.
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Continuous oral pyridoxine compared to placebo for febrile seizures in children
Patient or population: Children with febrile seizures
Setting: Outpatients
Intervention: Continuous oral pyridoxine
Comparison: placebo
Outcomes Anticipated absolute effects* (95% CI) Relative
effect
(95% CI)
№ of
participants
(studies)
Quality of the
evidence
(GRADE)
Comments
Risk with
placebo
Risk with Continuous
oral pyridoxine
Recurrent seizure at 6
months
154 per
1,000
72 per 1,000
(23 to 228)
RR 0.47
(0.15 to
1.48)
107
(1 RCT)
⊕⊕⊝⊝
Low1,2
 
Recurrent seizure at 12
months
192 per
1,000
127 per 1,000
(52 to 310)
RR 0.66
(0.27 to
1.61)
107
(1 RCT)
⊕⊕⊝⊝
Low1,2
 
Recurrent seizure at 18
months Not reported NA
 
Recurrent seizure at 24
months Not reported NA
 
Recurrent seizure at 36
months Not reported NA
 
Recurrent seizure at 48
months Not reported NA
 
Recurrent seizure at 60
months or greater Not reported NA
 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk (the event rate in the
control group) and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; NA: Not applicable; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of
the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate
of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different
from the estimate of effect
Footnotes
1 Downgraded once due to risk of bias: risk of attrition bias.
2 Downgraded once due to imprecision: relative effect has very large conf idence interval
7 Intermittent oral ibuprofen compared to placebo for febrile seizures in children
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Intermittent oral ibuprofen compared to placebo for febrile seizures in children
Patient or population: Children with febrile seizures
Setting: Outpatients
Intervention: Intermittent oral ibuprofen
Comparison: placebo
Outcomes Anticipated absolute effects* (95% CI) Relative
effect
(95% CI)
№ of
participants
(studies)
Quality of the
evidence
(GRADE)
Comments
Risk with
placebo
Risk with Intermittent
oral ibuprofen
Recurrent seizure at 6
months
210 per
1,000
233 per 1,000
(145 to 380)
RR 1.11
(0.69 to
1.81)
230
(1 RCT)
⊕⊕⊕⊕
High
 
Recurrent seizure at 12
months
294 per
1,000
279 per 1,000
(185 to 421)
RR 0.95
(0.63 to
1.43)
230
(1 RCT)
⊕⊕⊕⊕
High
 
Recurrent seizure at 18
months Not reported NA
 
Recurrent seizure at 24
months
387 per
1,000
325 per 1,000
(228 to 460)
RR 0.84
(0.59 to
1.19)
230
(1 RCT)
⊕⊕⊕⊕
High
 
Recurrent seizure at 36
months Not reported NA
 
Recurrent seizure at 48
months Not reported NA
 
Recurrent seizure at 60
months or greater Not reported NA
 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk (the event rate in the
control group) and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; NA: Not applicable; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of
the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate
of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different
from the estimate of effect
Footnotes
8 Intermittent oral clobazam compared to placebo for febrile seizures in children
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Intermittent oral clobazam compared to placebo for febrile seizures in children
Patient or population: Children with febrile seizures
Setting: Outpatients
Intervention: Intermittent oral clobazam
Comparison: placebo
Outcomes Anticipated absolute effects* (95% CI) Relative
effect
(95% CI)
№ of
participants
(studies)
Quality of the
evidence
(GRADE)
Comments
Risk with
placebo
Risk with Intermittent
oral clobazam
Recurrent seizure at 6
months
833 per
1,000
300 per 1,000
(167 to 533)
RR 0.36
(0.20 to
0.64)
60
(1 RCT)
⊕⊕⊝⊝
Low1,2
 
Recurrent seizure at 12
months Not reported NA
 
Recurrent seizure at 18
months Not reported NA
 
Recurrent seizure at 24
months Not reported NA
 
Recurrent seizure at 36
months Not reported NA
 
Recurrent seizure at 48
months Not reported NA
 
Recurrent seizure at 60
months or greater Not reported NA
 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk (the event rate in the
control group) and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; NA: Not applicable; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of
the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate
of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different
from the estimate of effect
Footnotes
1 Downgraded once due to risk of bias: unclear details regarding allocation concealment, blinding and attrition.
2 Downgraded once due to applicability: very high recurrence rate in the placebo group, higher than expected.
9 Continuous zinc sulfate for 6 months compared to placebo for febrile seizures in children
8 Prophylactic drug management for febrile seizures in children
45 / 65
Continuous zinc sulfate for 6 months compared to placebo for febrile seizures in children
Patient or population: Children with febrile seizures
Setting: Outpatients
Intervention: Continuous zinc sulfate for 6 months
Comparison: placebo
Outcomes Anticipated absolute effects* (95% CI) Relative
effect
(95% CI)
№ of
participants
(studies)
Quality of the
evidence
(GRADE)
Comments
Risk with
placebo
Risk with Continuous zinc
sulfate for 6 months
Recurrent seizure at 6
months Not reported NA
 
Recurrent seizure at 12
months
380 per
1,000
220 per 1,000
(118 to 414)
RR 0.58
(0.31 to
1.09)
100
(1 RCT)
⊕⊕⊕⊕
High
 
Recurrent seizure at 18
months Not reported NA
 
Recurrent seizure at 24
months Not reported NA
 
Recurrent seizure at 36
months Not reported NA
 
Recurrent seizure at 48
months Not reported NA
 
Recurrent seizure at 60
months or greater Not reported NA
 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk (the event rate in the
control group) and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; NA: Not applicable; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of
the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate
of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different
from the estimate of effect
Footnotes
10 Intermittent rectal diclofenac compared to placebo followed after 8 hours by oral ibuprofen, acetaminophen
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Intermittent rectal diclofenac compared to placebo followed after 8 hours by oral ibuprofen, acetaminophen or placebo for
febrile seizures in children
Patient or population: Children with febrile seizures
Setting: Outpatients
Intervention: Intermittent rectal diclofenac
Comparison: placebo followed after 8 hours by oral ibuprofen, acetaminophen or placebo
Outcomes Anticipated absolute effects* (95% CI) Relative
effect
(95% CI)
№ of
participants
(studies)
Quality of the
evidence
(GRADE)
Comments
Risk with placebo followed after 8
hours by oral ibuprofen,
acetaminophen or placebo
Risk with
Intermittent rectal
diclofenac
Recurrent seizure
at 6 months
149 per 1,000 119 per 1,000
(63 to 231)
RR 0.80
(0.42 to
1.55)
231
(1 RCT)
⊕⊕⊕⊕
High
 
Recurrent seizure
at 12 months
237 per 1,000 163 per 1,000
(95 to 275)
RR 0.69
(0.40 to
1.16)
231
(1 RCT)
⊕⊕⊕⊕
High
 
Recurrent seizure
at 18 months
272 per 1,000 196 per 1,000
(122 to 315)
RR 0.72
(0.45 to
1.16)
231
(1 RCT)
⊕⊕⊕⊕
High
 
Recurrent seizure
at 24 months
281 per 1,000 222 per 1,000
(143 to 348)
RR 0.79
(0.51 to
1.24)
231
(1 RCT)
⊕⊕⊕⊕
High
 
Recurrent seizure
at 36 months Not reported NA
 
Recurrent seizure
at 48 months Not reported NA
 
Recurrent seizure
at 60 months or
greater
Not reported NA  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk (the event rate in the
control group) and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; NA: Not applicable; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of
the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate
of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different
from the estimate of effect
Footnotes
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Continuous phenobarbitone compared to intermittent rectal/oral diazepam for febrile seizures in children
Patient or population: Children with febrile seizures
Setting: Outpatients
Intervention: Continuous phenobarbitone
Comparison: intermittent rectal/oral diazepam
Outcomes Anticipated absolute effects* (95% CI) Relative
effect
(95% CI)
№ of
participants
(studies)
Quality of the
evidence
(GRADE)
Comments
Risk with intermittent
rectal/oral diazepam
Risk with Continuous
phenobarbitone
Recurrent seizure at 6
months Not reported NA
 
Recurrent seizure at
12 months
155 per 1,000 229 per 1,000
(116 to 455)
RR 1.48
(0.75 to
2.94)
145
(1 RCT)
⊕⊕⊝⊝
Low1
 
Recurrent seizure at
18 months
80 per 1,000 100 per 1,000
(29 to 350)
RR 1.25
(0.36 to
4.38)
100
(1 RCT)
⊕⊝⊝⊝
Very low1,2
 
Recurrent seizure at
24 months Not reported NA
 
Recurrent seizure at
36 months Not reported NA
 
Recurrent seizure at
48 months Not reported NA
 
Recurrent seizure at
60 months or greater Not reported NA
 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk (the event rate in the
control group) and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; NA: Not applicable; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of
the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate
of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different
from the estimate of effect
Footnotes
1 Downgraded twice due to serious risk of bias: the single RCT contributing evidence had unsatisfactory allocation
concealment and no blinding.
2 Downgraded once due to imprecision: relative effect has very large conf idence interval.
12 Intermittent rectal diazepam compared to intermittent rectal valproate for febrile seizures in children
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Intermittent rectal diazepam compared to intermittent rectal valproate for febrile seizures in children
Patient or population: Children with febrile seizures
Setting: Outpatients
Intervention: Intermittent rectal diazepam
Comparison: intermittent rectal valproate
Outcomes Anticipated absolute effects* (95% CI) Relative
effect
(95% CI)
№ of
participants
(studies)
Quality of the
evidence
(GRADE)
Comments
Risk with intermittent
rectal valproate
Risk with Intermittent
rectal diazepam
Recurrent seizure at 6
months
88 per 1,000 123 per 1,000
(51 to 304)
RR 1.41
(0.58 to
3.47)
169
(1 RCT)
⊕⊝⊝⊝
Very low1,2
 
Recurrent seizure at 12
months
175 per 1,000 259 per 1,000
(144 to 467)
RR 1.48
(0.82 to
2.67)
169
(1 RCT)
⊕⊕⊝⊝
Low1
 
Recurrent seizure at 18
months Not reported NA
 
Recurrent seizure at 24
months Not reported NA
 
Recurrent seizure at 36
months Not reported NA
 
Recurrent seizure at 48
months Not reported NA
 
Recurrent seizure at 60
months or greater Not reported NA
 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk (the event rate in the
control group) and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; NA: Not applicable; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of
the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate
of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different
from the estimate of effect
Footnotes
1 Downgraded twice due to serious risk of bias: the single RCT contributing evidence had unsatisfactory allocation
concealment and no blinding.
2 Downgraded once due to imprecision: relative effect has very large conf idence interval.
13 Intermittent oral diazepam compared to oral clobazam for febrile seizures in children
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Intermittent oral diazepam compared to oral clobazam for febrile seizures in children
Patient or population: Children with febrile seizures
Setting: Outpatients
Intervention: Intermittent oral diazepam
Comparison: oral clobazam
Outcomes Anticipated absolute effects* (95% CI) Relative
effect
(95% CI)
№ of
participants
(studies)
Quality of the
evidence
(GRADE)
Comments
Risk with oral
clobazam
Risk with Intermittent
oral diazepam
Recurrent seizure at 6
months Not reported NA
 
Recurrent seizure at 12
months
42 per 1,000 96 per 1,000
(26 to 356)
RR 2.28
(0.62 to
8.42)
143
(2 RCTs)
⊕⊕⊝⊝
Low1,2
 
Recurrent seizure at 18
months Not reported NA
 
Recurrent seizure at 24
months Not reported NA
 
Recurrent seizure at 36
months Not reported NA
 
Recurrent seizure at 48
months Not reported NA
 
Recurrent seizure at 60
months or greater Not reported NA
 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk (the event rate in the
control group) and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; NA: Not applicable; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of
the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate
of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different
from the estimate of effect
Footnotes
1 Downgraded once due to risk of bias: Unsatisfactory allocation concealment and blinding.
2 Downgraded once due to imprecision: relative effect has very large conf idence interval.
Additional tables 
1 Treatment adherence
Study Treatment
groups
AssessedMethod Outcome Treatment adjusted
based on adherence
assessment?
Autret 1990 -DZP (oral)
-PCB
Yes Treatment diary 7% (1/15) of the patients with relapses in DZP
group were adherent versus 39% (7/18) in
PCB group
No
Bacon 1981 -PT
-PB (cont.)
-PCB
Yes Saliva and
plasma
Recurrence was positively related to median
drug levels for PB, but not related for PT
PB: 0/4 (0%) at < 5 mg/l; 5/19 (26%) at 5 - 8
mg/l; 5/25 (20%) at > 8 mg/l
PT: 3/9 (33%) at < 0.5 mg/l, 9/19 (47%) at 0.5
- 1.0 mg/l, 4/19 (21% 0 at > 1.0 mg/l
Yes
Bajaj 2005 -CBZ
-PCB
No      
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Study Treatment
groups
AssessedMethod Outcome Treatment adjusted
based on adherence
assessment?
Camfield 1980 -PB (cont.)
-PCB
Yes Riboflavin urine
check, and serum
PB
Urine samples available in 65% (PB) and 56%
(PCB), more than 90% of all samples tested
positive.
PB levels: mean 1.3 - 1.5 mg/dl, 70% - 81%
within therapeutic range (≥ 1.0 mg/dl)
Yes
Daugbjerg
1990
-DZP
(rectal)
-VP
No
     
Fallah 2015
-ZNC
-PCB
No      
Farwell 1990 -PB (cont.)
-PCB
Yes Riboflavin urine
check, PB blood
levels
Riboflavin results not reported
2/3 (66%) of PB blood levels tested were
above 645.9 micromole/l or 15 microgram/ml
Yes
Ghazavi 2016
-CBZ
-DZP (oral)
No      
Garcia 1984 -DZP
(rectal)
-PB (cont.)
No
     
Heckmatt 1976 -PB (cont.)
-NT
Yes PB plasma levels 82% (40/49) had a mean PB plasma level
above 65 micromole/l. All 4 recurrences in the
PB group occurred in children with levels
above 65 micromole/l
Yes
Khosroshahi
2011
-DZP (oral)
-CBZ
No      
Knudsen 1985 -DZP
(rectal)
-NT
Yes Historically in
case of
recurrence
Unclear report: "Parents treated the seizure as
prescribed in 56/77 (72%) of the cases."
Origin of the denominator is unclear as 21
recurrences occurred in DZP and 77 in NT
No
Mackintosh
1970
-PB (int.)
-PCB
No      
Mamelle 1984 -PB (cont.)
-VP
-PCB
Yes Blood levels Unclear report. Yes
McKiernan
1981
-PDX
-PCB
Yes Historically and
counting of
tablets used
Not reported. Yes
McKinlay 1989 -PB (cont.)
-VP
-NT
Yes PB and VP serum
levels
PB: Level checked 25/41 (61%) of children
Therapeutic level at time of recurrence 5/12
(42%) Level in those with non-recurrence:
9/29 therapeutic, 11/29 subtherapeutic, 9/29
not done
VP: Level checked 36/50 (72%) of children
Therapeutic level at time of recurrence 12/20
(60%) Level in children with non-recurrence:
13/30 therapeutic, 6/30 subtherapeutic, 11/30
not done
No
Mosquera 1987 -DZP
(rectal)
-VP
-NT
No
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Study Treatment
groups
AssessedMethod Outcome Treatment adjusted
based on adherence
assessment?
Ngwane 1980 -PB (cont.)
-VP
Yes Blood levels
(random
moments)
35 measure in 28 of 39 included children
(72%): 16 in PB of which 4 (25%) below
therapeutic range and 19 in VP of which 1
(5%) below therapeutic range
No
Pavlidou 2006 -DZP
(rectal)
-NT
No
     
Ramakrishnan
1986
-PB (cont.)
-PB (int.)
-DZP (oral)
-NT
No
     
Rosman 1993 -DZP (oral)
-PCB
Yes Riboflavin urine
check
1257 DZP samples, 66% of all reported fever
days, 96% of samples tested positive
982 PCB samples, 95% of all reported fever
days, 95% of samples tested positive
No
Salehiomran
2016
-DZP (oral)
-PB (cont.)
No      
Strengell 2009 -DCF
-PCB
No      
Taghdiri 2011 -DZP
(rectal)
-NT
No
     
Thilothammal
1993
-PB (cont.)
-PCB
Yes Counting sachets "Poor compliance" in 2/30 (7%) PB children
and in 1/30 (3%) PCB children.
All children with "poor compliance" also had a
recurrence
No
Uhari 1995 -DZP
-PCB
No      
Van
Stuijvenberg
1998
-IBU
-PCB
No
     
Verrotti 2004 -DZP (oral)
-NT
Yes Unclear, asked at
recurrence
All 5 recurrences in DZP group were non-
compliant
No
Williams 1979 -VP
-NT
Yes Random VP
plasma samples
Checked in 21/30 (70%) VP children: All
showed measurable levels, but 2 below target
concentration
No
Wolf 1977 -PB (cont.)
-PB (int.)
-NT
Yes 4-monthly blood
check in the
continuous PB
group
78 of 106 cont. PB children (74%) had PB
concentrations above target in at least 50% of
their samples. These include 5 of the 7
children (71%) who had a recurrence in this
group.
Yes
Footnotes
CBZ = clobazam; DCF = diclofenac; DZP = diazepam; IBU = ibuprofen; NT = no treatment; PB = phenobarbitone; PCB =
placebo; PDX = pyridoxine; PT = phenytoin; VP = valproate; ZNC = zinc sulfate; cont. = continuous; int. = intermittent
2 Unwanted medication effects
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First author Number ofChildren Adverse medication effects, as reported in article
Autret 1990 177
Hyperactivity (defined as agitation and inability to remain still), significantly (P < 0.003)
more frequent in diazepam group (138 vs 34 days). No significant differences noted for
normal vigilance or drowsiness; normal staggering or impossible "walking". One sudden
unexpected death in placebo group.
 
Bacon 1981
138, 43 control,
48
phenobarbitone,
48 phenytoin
Rash in 1 child on phenobarbitone, ataxia in 5 on phenytoin. Behavioural items:
whinginess; crying a lot, bad temper, tantrums, dislike of being left, unsteadiness, desire
for cuddling, difficulty feeding, noisiness, thumb sucking. No significant difference for any
of these items between phenobarbitone/phenytoin or placebo group. Any behavioural
change attributed to hospitalisation.
Bajaj 2005 60
Drug reactions Group A (clobazam) Group B (placebo); n (%) n (%): Weakness 1 (3.3) 11
(33.3); Irritability 4 (13.3) 1 (3.3); Sedation 5 (16.7) 5 (16.7); Anorexia 2 (6.6) 5 (16.7);
Nausea and vomiting 0 - 2 (6.6); Abdominal pain 0 - 1 (3.3); Diarrhoea 1 (3.3) 3 (10);
Headache 1 (3.3) 5 (16.7)
Camfield 1980 79
At 12 months no difference between phenobarbitone and placebo groups for behavioural
change or sleep disturbance. Placebo group, transient adverse effects in 7 of 30.
Phenobarbitone group, transient adverse effects 15 of 35. Significant negative correlation
between phenobarbitone serum level and memory concentration subscores on Binet
scores. Lower comprehension scores showed significant correlation with length of
phenobarbitone treatment (but n = 7 at 8 months and 9 at 12 months, therefore small
numbers).
Daugbjerg
1990
¬
169
Diazepam seen in 42 (47%) as follows: sedation 33 (37%), ataxia 42 (47%), hyperkinesia
21 (24%), diarrhoea, urge to defecate 1 (1%), depression 1 (1%). Valproic acid: sedation
9 (11%), ataxia 3 (4%), hyperkinesia 6 (7%), diarrhoea, urge to defecate 14 (18%).
Vomiting 1 (1%), bleeding per rectum 1 (1%), abdominal pain 3 (4%), aggressiveness 3
(4%).
Fallah 2015 100
No serious side effects were witnessed in the 2 groups. Gastrointestinal side effects
including vomiting in 5 (10%) children, heartburn in 2 (4%) and abdominal pain in 1 (2%)
child were seen in 16% of the zinc sulfate group. All of the side effects were well tolerated
and disappeared in 2 to 3 wks and supplementation continued. Vomiting occurred in 2
children (4%) in the control group.
 
Farwell 1990 217
Investigators compared intelligence quotients (IQs) of a group randomly assigned to
phenobarbitone to a group randomly assigned to placebo. After 2 years mean IQ 8.4
points lower in phenobarbitone group (95% CI ?13.3 to -3.5, P + 0.006). 6 months later
after discontinuing medication IQ 5.2 points lower in phenobarbitone group (95% CI -10.5
to 0.04, P = 0.052). Proportion remaining seizure-free did not differ significantly between
treatment groups. 14 total sleep time, night awakenings and lengthy awakenings
compared in phenobarbitone and placebo groups. No difference noted between groups
except subset of predisposed children did experience an increase in night awakenings,
(that is, those already recorded to have frequent sleep disturbances at study entry). 35:
Retesting of group after school entry. Phenobarbitone treated group had Wide Range
Achievement Test (WRAT-R) reading achievement score significantly lower than placebo
group: 87.6 v 95.6; P = 0.007. No significant difference for IQ on Stamford Binet.
Garcia 1984 100¬ Adverse effects: Diazepam 5 (10%), phenobarbitone 3 (6%). Nature of adverse effectsnot stated.
Ghazavi 2016 71 Ataxia: Diazepam 4/35 (11%) clobazam 1/36 (3%)
Heckmatt
1976 161
Overall, 39 of 88 stopped taking phenobarbital:16 behaviour (over-activity, unpleasant
behaviour, temper, not sleeping) 12 improved; 23 for a variety of reasons, e.g.
drowsy/unsteady. 3 in control group reported behaviour problems.
Knudsen 1985 152 No severe adverse effects. Mild transient: 36% sedation, 15% euphoria, 8% ataxia, 2%aggression. adverse effects not addressed in report on follow-up.¬
Khosroshahi
2011 72
The adverse effects of clobazam were noted to be lower than with diazepam. Sedation
was noted more often with diazepam compared to clobazam (P < 0.0001) - further details
are not given.
Mamelle 1984 ¬ Adverse effects not addressed.
Mackintosh
1970 32 Adverse effects not addressed.¬
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First author Number ofChildren Adverse medication effects, as reported in article
McKiernan
1981 107 Adverse effects not addressed.¬
McKinlay 1989 151
13 of 41 on phenobarbitone had disturbed behaviour and/or drowsiness; 1 vomiting; 2
rash; 1 unacceptable taste. 8 stopped treatment; 3 within 3 months. 5 of 50 on Valproate;
drowsy initially; 2 behavioural problems; 1 vomited; 1 diarrhoea. 2 stopped taking drug. 16
control group adverse effects not addressed.
Mosquera
1987 69 Adverse effects not addressed.¬
Ngwane 1980 43 5 of 23 on phenobarbitone had adverse effects within 72 hours; 2 of these drug withdrawn(details not given). 4 of 20 on Valproate, adverse effects - most commonly diarrhoea.
Pavlidou 2006 139 Adverse effects were only reported in the diazepam group. These were described as mildand transient and included somnolence and irritability.
Ramakrishnan
1986 120 Adverse effects not addressed.¬
Rosman 1993 288
Of 135 children on placebo: 1 “moderate” maculopapular rash.153 on diazepam with 59
(39%) at least moderate adverse effects: ataxia 30%, lethargy 29%, irritability 24%.
Moderate adverse effects: unclear speech 6%; hyperactivity 6%, insomnia 5%,
hallucinations 0.7%. (Percentages of those 59 (39%) overall who had adverse effects).
Mild adverse effects paralleled moderate numbers.
Salehiomran
2016 145
Side effects of phenobarbital like hyperkinesia, irritability, and restlessness were observed
in some children but diazepam-related side effects except sedation were not seen.
Strengell 2009 231 Adverse effects not addressed.
Van
Stuijvenberg
1998
230 Adverse effects not addressed.¬
Thilothammal
1993 90
“Intolerable” side effects presented in 2 of 30 children with simple febrile seizures on
phenobarbitone and 1 of 30 children with atypical febrile seizures. Recorded adverse
effects were “mainly hyperkinetic behaviour, extreme irritability, fussiness and
aggressiveness”. Details of percentages are not given.
Uhari 1995 180 children Adverse effects not addressed.
Verrotti 2004 110
Adverse effects were only reported from the treatment group, including ataxia, lethargy
and irritability: 14 children (31.1%) had ataxia, 13 (28.8%) presented lethargy and 11
children (24.4%) had irritability. These adverse effects lasted no more than 36 hours.
Williams 1979 58
7 of 30 children taking Valproate (23%) had adverse effects: 4 diarrhoea or vomiting; 1
increased appetite; 1 increased daytime activity, night terrors and confusion; 1 anorexia,
withdrawn and crying. adverse effects in control group not detailed.
 
Wolf 1977 355
Phenobarbitone 34 of 109 (32%) discontinued continuous phenobarbitone, reasons as
follows:16% hyperactivity; 1% irritability; 3% rash; 2% lethargy; 10% parental non-
compliance. Long-term effect of phenobarbitone on cognitive function: Group of 50
matched for age, sex, rash and socio-economic status for difference cognitive function to
median age of 57.5 months (phenobarbitone-treated children) and 59.6 months (children
not receiving phenobarbitone).
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Classification pending references
Data and analyses 
1 Intermittent oral or rectal diazepam versus placebo or no treatment
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
1.1 Recurrent seizure @ 6 months 6 1151 Risk Ratio(M-H, Fixed, 95% CI) 0.64 [0.48, 0.85]
   1.1.1 Intermittent oral diazepam 2 516 Risk Ratio(M-H, Fixed, 95% CI) 0.70 [0.45, 1.11]
   1.1.2 Intermittent rectal diazepam 4 635 Risk Ratio(M-H, Fixed, 95% CI) 0.59 [0.41, 0.86]
1.2 Recurrent seizure @ 12 months 8 1416 Risk Ratio(M-H, Fixed, 95% CI) 0.69 [0.56, 0.84]
   1.2.1 Intermittent oral diazepam 3 701 Risk Ratio(M-H, Fixed, 95% CI) 0.72 [0.53, 0.99]
   1.2.2 Intermittent rectal diazepam 5 715 Risk Ratio(M-H, Fixed, 95% CI) 0.66 [0.50, 0.86]
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1.3 Recurrent seizure @ 18 months 1   Risk Ratio(M-H, Fixed, 95% CI) No totals
   1.3.1 Intermittent rectal diazepam 1   Risk Ratio(M-H, Fixed, 95% CI) No totals
1.4 Recurrent seizure @ 24 months 4 739 Risk Ratio(M-H, Fixed, 95% CI) 0.73 [0.56, 0.95]
   1.4.1 Intermittent oral diazepam 2 516 Risk Ratio(M-H, Fixed, 95% CI) 0.62 [0.45, 0.85]
   1.4.2 Intermittent rectal diazepam 2 223 Risk Ratio(M-H, Fixed, 95% CI) 1.13 [0.67, 1.90]
1.5 Recurrent seizure @ 36 months 1   Risk Ratio(M-H, Fixed, 95% CI) No totals
   1.5.1 Intermittent rectal diazepam 1   Risk Ratio(M-H, Fixed, 95% CI) No totals
1.6 Recurrent seizure @ 48 months 1   Risk Ratio(M-H, Fixed, 95% CI) No totals
   1.6.1 Intermittent oral diazepam 1   Risk Ratio(M-H, Fixed, 95% CI) No totals
1.7 Recurrent seizure @ 60-72
months 1   Risk Ratio(M-H, Fixed, 95% CI) No totals
   1.7.1 Intermittent oral diazepam 1   Risk Ratio(M-H, Fixed, 95% CI) No totals
2 Continuous phenobarbitone versus placebo or no treatment
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
2.1 Recurrent seizure @ 6 months 6 833 Risk Ratio(M-H, Fixed, 95% CI) 0.59 [0.42, 0.83]
2.2 Recurent seizure @ 12 months 7 807 Risk Ratio(M-H, Fixed, 95% CI) 0.54 [0.42, 0.70]
2.3 Recurent seizure @ 18 months 2 264 Risk Ratio(M-H, Fixed, 95% CI) 0.77 [0.56, 1.05]
2.4 Recurent seizure @ 24 months 3 533 Risk Ratio(M-H, Fixed, 95% CI) 0.69 [0.53, 0.89]
2.5 Recurrent seizure @ 60-72
months 1   Risk Ratio(M-H, Fixed, 95% CI) No totals
2.6 Behavioural changes 1 65 Risk Ratio(M-H, Fixed, 95% CI) 1.61 [0.79, 3.26]
3 Intermittent phenobarbitone versus placebo or no treatment
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
3.1 Recurrent seizure @ 6 months 2 281 Risk Ratio(M-H, Fixed, 95% CI) 1.37 [0.67, 2.81]
3.2 Recurent seizure @ 12 months 2 281 Risk Ratio(M-H, Fixed, 95% CI) 1.01 [0.65, 1.59]
3.3 Recurent seizure @ 24 months 1   Risk Ratio(M-H, Fixed, 95% CI) No totals
3.4 Recurrent seizure @ 60-72
months 1   Risk Ratio(M-H, Fixed, 95% CI) No totals
4 Continuous oral phenytoin versus placebo
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
4.1 Recurent seizure @ 12 months 1   Risk Ratio(M-H, Fixed, 95% CI) No totals
5 Continuous oral valproate versus placebo or no treatment
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
5.1 Recurrent seizure @ 6 months 2 156 Risk Ratio(M-H, Fixed, 95% CI) 1.20 [0.55, 2.62]
5.2 Recurrent seizure @ 12 months 4 255 Risk Ratio(M-H, Fixed, 95% CI) 0.82 [0.52, 1.29]
5.3 Recurrent seizure @ 18 months 1   Risk Ratio(M-H, Fixed, 95% CI) No totals
5.4 Recurrent seizure @ 24 months 2 156 Risk Ratio(M-H, Fixed, 95% CI) 1.26 [0.73, 2.18]
6 Continuous oral pyridoxine versus placebo
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
6.1 Recurrent seizure @ 6 months 1   Risk Ratio(M-H, Fixed, 95% CI) No totals
6.2 Recurrent seizure @ 12 months 1   Risk Ratio(M-H, Fixed, 95% CI) No totals
7 Intermittent oral ibuprofen versus placebo
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
7.1 Recurrent seizure @ 6 months 1   Risk Ratio(M-H, Fixed, 95% CI) No totals
7.2 Recurrent seizure @ 12 months 1   Risk Ratio(M-H, Fixed, 95% CI) No totals
7.3 Recurrent seizure @ 24 months 1   Risk Ratio(M-H, Fixed, 95% CI) No totals
8 Intermittent oral clobazam versus placebo
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
8.1 Recurrent seizure @ 6 months 1   Risk Ratio(M-H, Fixed, 95% CI) No totals
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9 Continuous zinc sulfate for 6 months versus placebo
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
9.1 Recurrent seizures @ 12 months1   Risk Ratio(M-H, Fixed, 95% CI) No totals
10 Intermittent rectal diclofenac versus placebo followed after 8 hours by oral ibuprofen, acetaminophen or
placebo
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
10.1 Recurrent seizures @ 6 months1   Risk Ratio(M-H, Fixed, 95% CI) No totals
10.2 Recurrent seizures @ 12
months 1   Risk Ratio(M-H, Fixed, 95% CI) No totals
10.3 Recurrent seizures @ 18
months 1   Risk Ratio(M-H, Fixed, 95% CI) No totals
10.4 Recurrent seizures @ 24
months 1   Risk Ratio(M-H, Fixed, 95% CI) No totals
11 Continuous phenobarbitone versus intermittent rectal/oral diazepam
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
11.1 Recurrent seizure @ 12
months 1   Risk Ratio(M-H, Fixed, 95% CI) No totals
11.2 Recurrent seizure @ 18
months 1   Risk Ratio(M-H, Fixed, 95% CI) No totals
12 Intermittent rectal diazepam versus intermittent rectal valproate
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
12.1 Recurrent seizure @ 6 months 1   Risk Ratio(M-H, Fixed, 95% CI) No totals
12.2 Recurrent seizure @ 12
months 1   Risk Ratio(M-H, Fixed, 95% CI) No totals
13 Intermittent oral diazepam versus oral clobazam
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
13.1 Recurrent seizure @ 12
months 2 143 Risk Ratio(M-H, Fixed, 95% CI) 2.28 [0.62, 8.42]
Figures
Figure 1 (Analysis 1.1) 
Caption
Funnel plot of comparison: 1 Intermittent oral or rectal diazepam versus placebo or no treatment to recurrence at 6 months.
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Figure 2 (Analysis 1.2) 
Caption
Funnel plot of comparison: 1 Intermittent oral or rectal diazepam versus placebo or no treatment at recurrence at 12 months.
Figure 3 (Analysis 2.1) 
Caption
Funnel plot of comparison 2: continuous phenobarbitone versus placebo or no treatment to recurrence at 6 months: no
evidence of publication bias.
Figure 4 (Analysis 2.2) 
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Caption
Funnel plot of comparison 2: continuous phenobarbitone versus placebo or no treatment to recurrence at 12 months:
evidence of publication bias.
Figure 5
Caption
Seizure recurrence in the control groups of the included trials, red lines indicate median recurrence rates at each time point,
by control group type.
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Feedback 
Appendices 
1 Search strategies
CENTRAL search strategy
#1¬¬¬¬¬¬¬¬ (febrile seizure*) or (febrile convulsion*)
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#2¬¬¬¬¬¬¬¬ MeSH descriptor Seizures, Febrile explode all trees
#3¬¬¬¬¬¬¬¬ (anticonvulsant*) OR (antiepilep*)
#4¬¬¬¬¬¬¬¬ MeSH descriptor Anticonvulsants explode all trees
#5¬¬¬¬¬¬¬¬ (acetaminophen OR paracetamol OR aspirin)
#6¬¬¬¬¬¬¬¬ MeSH descriptor Ibuprofen explode all trees
#7¬¬¬¬¬¬¬¬ MeSH descriptor Acetaminophen explode all trees
#8¬¬¬¬¬¬¬¬ (#1 OR #2)
#9¬¬¬¬¬¬¬¬ (#3 OR #4 OR #5 OR #6 OR #7)
#10¬¬¬¬¬¬ (#8 AND #9)
¬
MEDLINE search strategy
This strategy is based on the Cochrane Highly Sensitive Search Strategy for identifying randomised trials (Lefebvre 2009).
1. randomised controlled trial.pt.
2. controlled clinical trial.pt.
3. randomised.ab
4. placebo.ab.
5. clinical trials as topic.sh.
6. randomly.ab.
7. trial.ti.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. exp animals/ not humans.sh.
10. 8 not 9
11. febrile seizure$.tw.
12. febrile convulsion$.tw.
13. exp Seizures, Febrile/
14. 11 or 12 or 13
15. exp Anticonvulsants/
16. anticonvulsant$.tw.
17. antiepilep$.tw.
18. exp Acetaminophen/
19. (acetaminophen or paracetamol).tw.
20. exp Ibuprofen/
21. ibuprofen.tw.
22. 15 or 16 or 17 or 18 or 19 or 20 or 21
23. 10 and 14 and 22
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